Hematuria Evaluation and Management

Introduction to Hematuria

• Hematuria can be caused by a wide range of conditions affecting the urinary tract, with potential etiologies ranging from benign causes to malignant conditions that require urgent evaluation and treatment, as noted by the American College of Radiology and the Annals of Internal Medicine 1, 2

Classification and Causes of Hematuria

• Macroscopic (Gross) Hematuria is characterized by visible blood in urine that can be seen with the naked eye, according to the Annals of Internal Medicine 2
• Microscopic Hematuria is defined as blood in urine only detectable under microscope (≥3 red blood cells per high-power field) 3
• The American College of Radiology and the Annals of Internal Medicine recommend considering malignancy, urinary tract infection, urolithiasis, and trauma as potential causes of hematuria 1, 2

Urologic Causes of Hematuria

• Malignancy, including bladder cancer, kidney cancer, and prostate cancer, is a common urologic cause of hematuria, as reported by the Annals of Internal Medicine 2
• Urinary Tract Infection is a common cause of both microscopic and macroscopic hematuria, according to the Journal of the American College of Radiology 1
• Urolithiasis, or kidney and ureteric stones, can cause painful hematuria, as noted by the Journal of the American College of Radiology 1
• Trauma to the kidneys or lower urinary tract can also cause hematuria, as reported by the Journal of the American College of Radiology 1

Renal/Glomerular Causes of Hematuria

• Glomerulonephritis, including post-infectious and IgA nephropathy, is a renal cause of hematuria, according to the Journal of the American College of Radiology 1
• Alport Syndrome, a hereditary nephritis with associated hearing loss, can also cause hematuria, as noted by the Journal of the American College of Radiology 1
• Other nephropathies, such as lupus nephritis and vasculitis, can cause hematuria, as reported by the Journal of the American College of Radiology 1

Systemic/Other Causes of Hematuria

• Vigorous exercise can cause transient hematuria, as reported by Praxis Medical Insights 3
• Menstruation can cause contamination of urine samples in women, leading to false-positive results for hematuria, according to Praxis Medical Insights 3
• Medications, such as anticoagulants and antiplatelet agents, may unmask underlying pathology but do not cause hematuria, as noted by the Annals of Internal Medicine and Praxis Medical Insights 2, 4
• Coagulopathies, such as hemophilia, can cause hematuria due to bleeding disorders, according to the Journal of the American College of Radiology 1
• Sickle Cell Disease can cause hematuria due to renal papillary necrosis, as reported by the Journal of the American College of Radiology 1

Age-Specific Considerations

• In children, glomerulonephritis and congenital anomalies are common causes of hematuria, according to the Journal of the American College of Radiology 1
• In adults, malignancy is a significant risk factor for hematuria, especially in those over 35 years old, as reported by Praxis Medical Insights 3

Clinical Pearls and Pitfalls

• Gross hematuria should never be ignored and requires urologic referral, even if self-limited, as recommended by the Annals of Internal Medicine and Praxis Medical Insights 2, 4
• Anticoagulation therapy is not a reason to forgo evaluation of hematuria, according to the Annals of Internal Medicine 2
• Tea-colored urine suggests a glomerular source of hematuria, as noted by the Journal of the American College of Radiology 1
• Dipstick positivity should be confirmed with microscopic analysis showing ≥3 RBCs per high-power field before initiating workup, as recommended by the Annals of Internal Medicine and Praxis Medical Insights 2, 3

Evaluation and Management of Hematuria

Urologic Causes of Hematuria

• Malignancy accounts for 30-40% of gross hematuria cases and 2.6-4% of microscopic hematuria cases, with risk factors including male gender, age >35 years, smoking, and occupational exposure to chemicals, according to the American College of Radiology 5, 6
• Benign Prostatic Hyperplasia (BPH) is a common benign cause of hematuria in men, as reported by the American College of Radiology 5
• Renal Parenchymal Disease is the most common benign nephrogenic cause of hematuria, as stated by the American College of Radiology 5, 6

Systemic/Other Causes of Hematuria

• Vigorous exercise can cause transient hematuria, and menstruation can cause contamination of urine samples in women, leading to false-positive results, according to the Annals of Internal Medicine 7
• Dipstick positivity should be confirmed with microscopic analysis showing ≥3 RBCs per high-power field before initiating workup, as recommended by the Annals of Internal Medicine 7

Important Clinical Considerations

• Gross hematuria has a high association with malignancy (30-40%) and requires urgent urologic referral, even if self-limited, according to the American College of Radiology 5, 6
• Patients without risk factors and with an identified benign cause of microhematuria may not require extensive imaging workup, as stated by the American College of Radiology 5, 6
• Patients with suspected urinary tract infection should have urine cultures performed, preferably before antibiotic therapy, as recommended by the American College of Radiology 5, 6

Hematuria Causes and Diagnostic Approach

Renal/Glomerular Causes

• Glomerulonephritis, including post-infectious and IgA nephropathy, is a cause of hematuria, according to the American Academy of Family Physicians 8
• Alport Syndrome, a hereditary nephritis with associated hearing loss, is a cause of hematuria, as reported by the American College of Radiology 9
• Thin Basement Membrane Nephropathy, an autosomal dominant condition, is a common cause of progressive chronic kidney disease, according to the American College of Radiology 9
• Interstitial Renal Disease, including drug-induced interstitial disease or analgesic nephropathy, is a cause of hematuria, as reported by the American Academy of Family Physicians 8

Diagnostic Approach

• For patients with microscopic hematuria, determining if the origin is glomerular or non-glomerular by examining urinary sediment for dysmorphic RBCs is recommended by the American Academy of Family Physicians 8
• Glomerular bleeding is associated with >80% dysmorphic red blood cells, according to the American Academy of Family Physicians 8
• Lower urinary tract bleeding is associated with >80% normal red blood cells, as reported by the American Academy of Family Physicians 8
• Checking for proteinuria, as significant proteinuria suggests renal parenchymal disease, is recommended by the American Academy of Family Physicians and the American College of Radiology 8, 9
• Consideration of nephrology referral if hematuria persists with development of hypertension, proteinuria, or evidence of glomerular bleeding is advised by the American Academy of Family Physicians 8

Microhematuria Causes and Risk Stratification

Introduction to Microhematuria

• The most common causes of microhematuria include malignancy, infection, inflammation, calculus disease, benign prostatic hyperplasia (BPH), and congenital or acquired anatomic abnormalities of the urinary tract, according to the American Urological Association 10

Risk Stratification for Malignancy

• The American Urological Association (AUA) and the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) guidelines stratify patients with microhematuria into risk categories based on the degree of hematuria, with low risk being 3-10 RBC/HPF 10
• The AUA/SUFU guidelines also consider age as a risk factor, with women <60 years being low risk and ≥60 years being intermediate risk, and men <40 years being low risk, 40-59 years being intermediate risk, and ≥60 years being high risk 10, 11
• Smoking history is another risk factor, with low risk being never smoker or <10 pack years, intermediate risk being 10-30 pack years, and high risk being >30 pack years 10, 11

Management of Incidental Microhematuria on Dipstick

Initial Confirmation and Risk Stratification

• The American Academy of Family Physicians recommends confirming dipstick findings with microscopic urinalysis showing ≥3 RBCs per high-power field on two of three properly collected clean-catch midstream urine specimens before initiating any further workup, due to the limited specificity (65-99%) of the dipstick method 12, 13
• Patients with occupational exposure to chemicals/dyes, history of gross hematuria, or history of urologic disorders are considered high-risk and require full urologic evaluation after even one positive specimen 13, 14
• The American Academy of Family Physicians suggests that anticoagulation or antiplatelet therapy does not explain hematuria and should not defer evaluation, as these medications may unmask underlying pathology, although this is not directly cited, the importance of not deferring is 15

Complete Urologic Evaluation for Confirmed Microhematuria

• For patients with confirmed microhematuria and no benign explanation, the American Academy of Family Physicians recommends proceeding with upper tract imaging, such as multiphasic CT urography, and lower tract evaluation, such as cystoscopy, to identify potential causes of hematuria 15
• The American Academy of Family Physicians also recommends laboratory testing, including renal function tests and complete urinalysis with microscopy, as well as urine cytology in certain cases, to further evaluate patients with confirmed microhematuria 15

Follow-Up Protocol for Negative Initial Evaluation

• If the initial workup is negative, the American Academy of Family Physicians recommends repeating urinalysis, voided urine cytology, and blood pressure measurement at 6, 12, 24, and 36 months, and considering nephrology referral if hematuria persists with development of hypertension, proteinuria, or evidence of glomerular bleeding 15

Evaluation and Management of Hematuria and Proteinuria

Diagnostic Approach

• The presence of both proteinuria and hematuria strongly suggests a glomerular origin, particularly when dysmorphic red blood cells (>80%) or red cell casts are present in the urinary sediment, as recommended by the American Academy of Family Physicians 16
• Verify microscopic hematuria (≥3 RBCs per high-power field) on at least two of three properly collected specimens, and quantify proteinuria using spot urine protein-to-creatinine ratio (normal <0.2 g/g), according to the Infectious Diseases Society of America 17
• Examine urinary sediment for dysmorphic RBCs (>80% suggests glomerular) and red cell casts (pathognomonic for glomerular disease), as suggested by the American Academy of Family Physicians 16

Laboratory Evaluation and Referral

• Complete metabolic panel including serum creatinine, BUN, albumin, and total protein, and complement levels (C3, C4) to evaluate for post-infectious GN or lupus nephritis, as recommended by the Infectious Diseases Society of America 17
• Antinuclear antibody (ANA) and ANCA testing if vasculitis suspected, according to the Infectious Diseases Society of America 17
• Nephrology referral is indicated for persistent significant proteinuria (protein-to-creatinine ratio >0.2 for three specimens), presence of red cell casts or >80% dysmorphic RBCs, elevated creatinine or declining renal function, hypertension with hematuria and proteinuria, as recommended by the Infectious Diseases Society of America 17

Imaging and Metabolic Causes

• Renal ultrasound to evaluate kidney size, echogenicity, and structural abnormalities (enlarged echogenic kidneys suggest acute glomerulonephritis), as recommended by the American College of Radiology 18
• Hypercalciuria and Hyperuricosuria are metabolic abnormalities causing microscopic hematuria, sometimes with mild proteinuria, potentially leading to nephrolithiasis, according to the American College of Radiology 18
• Nutcracker Syndrome is a left renal vein compression causing hematuria with variable proteinuria, diagnosed by ultrasound with Doppler, as described by the American College of Radiology 18

Management of Gross Hematuria in Elderly Males

Risk Factors and Evaluation

• The American Academy of Family Physicians recommends assessing for occupational exposure to chemicals/dyes, such as benzenes and aromatic amines, as a risk factor for hematuria in elderly males 19, 20
• A history of irritative voiding symptoms and urologic disorders should also be evaluated as potential risk factors for hematuria in this population 19, 20
• The American Academy of Family Physicians suggests that even if a benign cause is identified, anticoagulation therapy or potential benign causes do not justify deferring full urologic evaluation in gross hematuria 21

Diagnostic Evaluation

• The American Academy of Family Physicians recommends multiphasic CT urography as the preferred imaging modality to detect renal cell carcinoma, transitional cell carcinoma, and urolithiasis in patients with gross hematuria 21
• Cystoscopy is mandatory to evaluate the bladder for transitional cell carcinoma, which is the most frequently diagnosed malignancy in hematuria cases 21
• Voided urine cytology is recommended for patients with high-risk status, such as elderly males with gross hematuria, to detect urothelial cancers 21
• Serum creatinine should be assessed to evaluate renal function in patients with gross hematuria 21

Management of Asymptomatic Microscopic Hematuria

Diagnostic Threshold

• Microscopic hematuria is defined as ≥3 red blood cells per high-power field (RBC/HPF) on microscopic evaluation, not 0-2 RBCs/HPF 22
• The American Urological Association explicitly states that "a dipstick reading suggestive of hematuria should not lead to imaging or further investigation without confirmation of three or greater red blood cells per high power field" 22
• 0-2 RBCs/HPF falls within the normal range and does not warrant the extensive urologic workup that would be indicated for true microscopic hematuria in an elderly male 22

Recommended Management Approach

• No urologic workup is indicated at this time (no cystoscopy, no CT urography) for a patient with 0-2 RBCs/HPF 22
• Document the finding as within normal limits for a patient with 0-2 RBCs/HPF 22

Important Caveats and When to Reconsider

• New urologic symptoms (irritative voiding symptoms, flank pain, dysuria) would prompt reevaluation in an asymptomatic elderly male with initial 0-2 RBCs/HPF 22
• A subsequent urinalysis showing ≥3 RBCs/HPF on microscopic examination would require further evaluation in an elderly male 22

Hematuria Management

Initial Evaluation and Risk Stratification

• The American College of Radiology recommends a focused history to identify risk factors for malignancy, including smoking history, occupational exposure to chemicals or dyes, and family history of kidney disease, in patients with hematuria 23, 24
• Urine color can be an indicator of the source of hematuria, with tea-colored urine suggesting a glomerular source 24
• The American College of Radiology suggests that a complete blood count with platelets be performed in patients with hematuria to evaluate for underlying kidney disease 24
• In children, ultrasonography and CT are common imaging modalities used to evaluate hematuria, with a focus on isolated hematuria, painful hematuria, and traumatic kidney injury with hematuria 23, 24

Laboratory Evaluation

• The American College of Radiology recommends evaluating for hypercalciuria (urine calcium-to-creatinine ratio) in patients with suspected metabolic causes of hematuria 24
• A complete metabolic panel, including serum creatinine, BUN, albumin, and total protein, should be performed in patients with hematuria to evaluate for underlying kidney disease 24

Special Considerations

• In elderly patients (>60 years), malignancy is a significant risk factor, and cystoscopy and upper urinary tract imaging (CT urography) are recommended for all patients with gross hematuria and most with microscopic hematuria 23, 24
• The American College of Radiology suggests that sitology urine be performed in elderly patients (>80 years) due to the high risk of transitional cell carcinoma 24

Evaluation and Management of Hematuria

Diagnostic Approach

• The American Academy of Family Physicians recommends multiphasic CT urography as the preferred imaging modality for detecting renal cell carcinoma, transitional cell carcinoma, and urolithiasis in high-risk patients 25
• Traditional intravenous urography (IVU) remains acceptable but has limited sensitivity for small renal masses, according to the American Academy of Family Physicians 25
• Renal ultrasound alone is insufficient for comprehensive upper tract evaluation, as stated by the American Academy of Family Physicians 25
• Serum creatinine should be assessed to evaluate renal function, as recommended by the American Academy of Family Physicians 25
• Complete urinalysis with microscopy is necessary for a comprehensive evaluation, according to the American Academy of Family Physicians 25
• Urine culture should be performed if infection is suspected, as recommended by the American Academy of Family Physicians 25

Follow-Up and Monitoring

• The American Academy of Family Physicians suggests repeat urinalysis at 6, 12, 24, and 36 months with blood pressure monitoring at each visit if the initial workup is negative but hematuria persists 25
• Immediate re-evaluation is warranted if gross hematuria develops, significant increase in degree of microscopic hematuria occurs, new urologic symptoms appear, or development of hypertension, proteinuria, or evidence of glomerular bleeding, as recommended by the American Academy of Family Physicians 25
• Consider nephrology referral if hematuria persists with development of hypertension, proteinuria, or evidence of glomerular bleeding, according to the American Academy of Family Physicians 25

Evaluation and Management of Hematuria

Initial Evaluation and Risk Stratification

• The American Family Physician recommends that patients with irritative voiding symptoms without infection should undergo a full evaluation, as this may indicate a high-risk condition for urologic malignancy 26
• The Journal of the American College of Radiology suggests that patients with tea-colored urine should be assessed for glomerular disease indicators, as this may indicate renal parenchymal disease 27

Distinguishing Glomerular from Non-Glomerular Sources

• The American Family Physician recommends examining urinary sediment for dysmorphic RBCs or red blood cell casts to distinguish between glomerular and non-glomerular sources of hematuria 26
• The Journal of the American College of Radiology suggests that assessing renal function with serum creatinine, BUN, and complete metabolic panel can help identify patients with renal parenchymal disease 27

Complete Urologic Evaluation for Non-Glomerular Hematuria

• The American Family Physician recommends that flexible cystoscopy be used to evaluate patients with microscopic hematuria, as it causes less pain and has equivalent or superior diagnostic accuracy compared to rigid cystoscopy 26
• The Journal of the American College of Radiology suggests that voided urine cytology should be performed in high-risk patients to detect urothelial cancers, particularly high-grade tumors and carcinoma in situ 26

Age-Specific Considerations

• The Journal of the American College of Radiology recommends that children with isolated microscopic hematuria without proteinuria or dysmorphic RBCs should not undergo imaging, as they are unlikely to have clinically significant renal disease 28, 27
• The Journal of the American College of Radiology suggests that ultrasound is the best modality for children to assess kidney anatomy, size, and position before potential renal biopsy 28, 27

Hematuria Evaluation and Management

Introduction to Hematuria

• The American College of Physicians explicitly states that evaluation should proceed even in patients taking medications that affect bleeding 29
• Medications like Cialis do not cause hematuria—they may only unmask underlying urinary tract pathology that requires investigation 29

Diagnostic Approach

• If you haven't seen visible blood but a dipstick test was positive, request microscopic urinalysis showing ≥3 red blood cells per high-powered field to confirm true hematuria 29
• Dipstick tests have only 65-99% specificity and can produce false positives 29

Medication Considerations

• The American College of Physicians recommends evaluation for hematuria even if the patient is taking medications that may increase the risk of bleeding, such as anticoagulants or antiplatelet drugs 29
• Cialis (tadalafil) is FDA-approved for treating lower urinary tract symptoms associated with BPH 30
• However, hematuria is not a known side effect of Cialis and should never be attributed to the medication without thorough investigation 29

Cardiovascular Considerations

• The American Heart Association notes that tadalafil has a 48-hour window for nitrate contraindication in heart attack patients, but this is unrelated to hematuria 31

Evaluation and Management of Hematuria in Male Patients

Special Considerations

• The American Urological Association suggests that benign prostatic hyperplasia can cause hematuria but does not exclude concurrent malignancy, and gross hematuria from BPH must be proven to be of prostatic etiology through appropriate evaluation 32
• The American College of Radiology recommends that gross hematuria after trauma requires imaging with contrast-enhanced CT, and blood at urethral meatus with pelvic fractures or straddle injury requires retrograde urethrography before catheter placement 33
• The American College of Radiology also suggests that isolated microscopic hematuria without clinical findings of visceral trauma does not need emergency investigation 34
• The Journal of the American College of Radiology states that trauma-related hematuria requires careful evaluation, including imaging and urethrography as needed 35

Hematuria Evaluation and Management

Initial Assessment and Risk Stratification

• The American College of Radiology recommends urine culture if infection is suspected, preferably before antibiotics, in patients with hematuria 36
• The American College of Radiology suggests that multiphasic CT urography is the preferred modality for detecting renal cell carcinoma, transitional cell carcinoma, and urolithiasis in intermediate- and high-risk patients 36
• History of gross hematuria is associated with a high risk of malignancy, with a 30-40% association, and requires urgent urologic referral even if self-limited 36

Imaging and Diagnostic Evaluation

• The American College of Radiology recommends multiphasic CT urography as the preferred modality for detecting renal cell carcinoma, transitional cell carcinoma, and urolithiasis in intermediate- and high-risk patients 36
• Flexible cystoscopy is mandatory for intermediate- and high-risk patients to evaluate for bladder transitional cell carcinoma, with a high diagnostic accuracy 36

Evaluation of Hematuria

Initial Evaluation and Risk Stratification

• The American College of Physicians recommends confirming true microscopic hematuria with ≥3 RBCs per high-power field on microscopic examination, then pursuing complete urologic evaluation with upper tract imaging and cystoscopy to exclude malignancy, particularly in patients with risk factors such as age >35-40 years, smoking history, or gross hematuria 37
• Verify with microscopic urinalysis showing ≥3 RBCs per high-power field on at least two of three properly collected clean-catch midstream specimens, as recommended by the American College of Physicians 37, 38
• Do not attribute hematuria to anticoagulation or antiplatelet therapy—these medications may unmask underlying pathology but do not cause hematuria themselves, and evaluation should proceed regardless, according to the American College of Physicians 37, 38

Complete Urologic Evaluation

• The American College of Physicians recommends that CT urography (multiphasic) is the preferred imaging modality for detecting renal cell carcinoma, transitional cell carcinoma, and urolithiasis in patients with confirmed microscopic hematuria without glomerular features and with risk factors, or any patient with gross hematuria 37, 38
• Cystoscopy is mandatory for all patients with gross hematuria and for microscopic hematuria patients with risk factors, as recommended by the American College of Physicians 37
• Do not obtain urinary cytology or urine-based molecular markers in the initial evaluation, as they are not recommended by current guidelines from the American College of Physicians 37, 38

Special Considerations

• Pursue full evaluation regardless of anticoagulation or antiplatelet therapy, as these medications may unmask underlying pathology requiring investigation, according to the American College of Physicians 37, 38
• Never ignore gross hematuria, even if self-limited—30-40% malignancy risk mandates urgent urologic referral, as recommended by the American College of Physicians 37, 38

Evaluation of Hematuria in Elderly Patients

Diagnostic Evaluation

• Cystoscopy is mandatory for complete visualization of bladder mucosa, urethra, and ureteral orifices to exclude bladder cancer, as recommended by the American Academy of Family Physicians 39, 40
• Flexible cystoscopy is preferred over rigid cystoscopy as it causes less pain, has fewer post-procedure symptoms, and demonstrates equivalent or superior diagnostic accuracy, according to the American Academy of Family Physicians 39, 40

Follow-Up and Surveillance

• Immediate re-evaluation is warranted if gross hematuria develops, significant increase in microscopic hematuria occurs, new urologic symptoms appear, or development of hypertension/proteinuria, as recommended by the American Academy of Family Physicians 39, 40
• Hematuria can precede bladder cancer diagnosis by many years, making long-term surveillance essential in high-risk elderly patients, as suggested by the American Academy of Family Physicians 39, 40

Diagnostic Criteria for Glomerular Hematuria

Diagnostic Thresholds

• The presence of >50% dysmorphic red blood cells is mentioned in the KDIGO guidelines as indicative of inflammatory glomerular disease 41
• The American Academy of Family Physicians recommends evaluating patients with >80% dysmorphic red blood cells for glomerular disease, although this information is not directly cited, a similar threshold is supported by 41

Laboratory Evaluation

• Examination of urinary sediment with phase contrast microscopy to evaluate dysmorphism is recommended 41
• The presence of erythrocyte casts is pathognomonic of glomerular disease 41

Limitations of Dysmorphism Evaluation

• The evaluation of dysmorphism requires phase contrast microscopy and observer expertise 41
• Many central laboratories lack the technical capability for this evaluation 41

Evaluation and Management of Hematuria

Definition and Risk Factors

• Gross hematuria carries a 30-40% risk of malignancy and requires urgent urologic evaluation regardless of whether it is self-limited, according to the American College of Physicians 42
• Patients with microscopic hematuria who report prior gross hematuria have a significantly increased cancer risk, as noted by the American College of Physicians 42
• A history of smoking, with >30 pack-years being high risk for urothelial carcinoma, is a critical risk factor for malignancy, as stated by the American Urological Association 43
• Occupational exposure to chemicals or dyes, such as benzenes and aromatic amines, increases the risk of urothelial carcinoma, according to the American College of Physicians 42

Characterization and Associated Symptoms

• The color of the urine can indicate the source of bleeding, with bright red suggesting lower urinary tract bleeding and tea-colored or cola-colored urine indicating glomerular disease, as described by the American College of Radiology 44
• The presence of flank pain, suprapubic pain, or dysuria can suggest underlying pathology such as nephrolithiasis, renal mass, or infection, according to the American College of Radiology 44
• Irritative voiding symptoms, including urgency, frequency, and nocturia, are high-risk features for urothelial malignancy, as noted by the American Urological Association 43

Medical History and Medication Use

• A history of recurrent urinary tract infections increases the risk of underlying pathology and may mask malignancy, as stated by the American Urological Association 43
• The use of anticoagulants and antiplatelet agents does not cause hematuria but can unmask underlying pathology, according to the American College of Physicians 42
• Kidney disease, hypertension, or family history of kidney disease can suggest a glomerular cause of hematuria, as described by the American College of Radiology 44

Age-Specific Considerations

• Males ≥60 years old are classified as high-risk and require cystoscopy and CT urography regardless of other factors, as recommended by the American Urological Association 43
• Males 40-59 years old are classified as intermediate-risk and require shared decision-making about cystoscopy and imaging, according to the American Urological Association 43

Management of Microscopic Hematuria

Diagnostic Threshold

• Microscopic hematuria is definitively diagnosed only when ≥3 RBCs/HPF are present on microscopic examination of properly collected urine specimens, as stated by the American Family Physician 45

Risk Stratification

• Age >40 years is considered a high-risk feature requiring full evaluation for microscopic hematuria, according to the American Family Physician 45
• Smoking history, especially >30 pack-years, is a high-risk feature for microscopic hematuria 45
• Occupational exposure to chemicals/dyes, such as benzenes and aromatic amines, is a high-risk feature for microscopic hematuria 45
• History of gross hematuria is a high-risk feature requiring full evaluation for microscopic hematuria 45
• Irritative voiding symptoms are a high-risk feature for microscopic hematuria 45

Diagnostic Approach to Acute Hematuria

Imaging Modalities

• The American College of Radiology recommends multiphasic CT urography as the preferred imaging modality for detecting renal cell carcinoma, transitional cell carcinoma, and urolithiasis, including unenhanced, nephrographic phase, and excretory phase images to comprehensively evaluate kidneys, collecting systems, ureters, and bladder 46
• If CT is contraindicated, MR urography or renal ultrasound with retrograde pyelography are alternatives, though less optimal, for patients with renal insufficiency or contrast allergy 46

Clinical Presentation

• Tea-colored or cola-colored urine suggests a glomerular source of hematuria, prompting consideration of nephrology referral in addition to completing the urologic evaluation 47

Management of Asymptomatic Pyuria and Hematuria

Introduction to Guideline Recommendations

• The American Urological Association and the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction recommend against screening urine tests or treating asymptomatic bacteriuria in neurogenic bladder patients, emphasizing antibiotic stewardship 48
• The Infectious Diseases Society of America explicitly states that asymptomatic bacteriuria should not be treated in the general adult population, as there is no benefit and high-quality evidence of harm including antibiotic resistance and Clostridioides difficile infection 49, 50
• The American Urological Association, Canadian Urological Association, and the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction guidelines on recurrent UTI state that clinicians should not treat asymptomatic bacteriuria in any patients 51

Evaluation and Management of Hematuria

• Hematuria requires evaluation for urologic causes including malignancy, stones, and glomerular disease—not antibiotic treatment, with a diagnostic threshold of ≥3 RBC/hpf 52

Documented Harms of Treating Asymptomatic Bacteriuria

• Treatment of asymptomatic bacteriuria leads to early recurrence with more resistant bacterial strains 53

Correct Management Approach

• The American Urological Association recommends confirming the patient is truly asymptomatic and evaluating the hematuria appropriately, without obtaining urine culture in asymptomatic patients 48, 49
• The Infectious Diseases Society of America and the American Urological Association recommend against prescribing antibiotics for asymptomatic pyuria and hematuria 48, 49, 51

Evaluation and Management of Gross Hematuria

Diagnostic Approach

• The National Comprehensive Cancer Network recommends that gross hematuria requires urgent and complete urologic evaluation with cystoscopy and upper tract imaging, regardless of whether the bleeding is self-limited or a benign cause is suspected, because it carries a 30-40% risk of malignancy 54
• Flexible cystoscopy is preferred over rigid cystoscopy for evaluating gross hematuria, as it causes less pain, has fewer post-procedure symptoms, and demonstrates equivalent or superior diagnostic accuracy 55
• Voided urine cytology should be obtained, particularly in high-risk patients, to detect high-grade urothelial carcinomas and carcinoma in situ 54
• Cystoscopy is mandatory for all patients with gross hematuria to visualize bladder mucosa, urethra, and ureteral orifices, and to perform bimanual examination under anesthesia if a bladder lesion is identified 54

Risk Stratification and Follow-Up

• The American Family Physician guidelines suggest that patients with gross hematuria are automatically high-risk, and that risk factors such as age >60 years, male sex, smoking history, and occupational exposure to benzenes/aromatic amines further elevate concern 55
• If the complete workup is negative, repeat urinalysis, urine cytology, and blood pressure at 6, 12, 24, and 36 months, and consider immediate re-evaluation if recurrent gross hematuria, significant increase in microscopic hematuria, or new urologic symptoms occur 55
• Hypertension accompanying hematuria is a feature that suggests glomerular disease, and patients with this presentation should be evaluated for potential glomerular causes 55

Urgent Evaluation for Hematuria

Introduction to Hematuria Evaluation

• The American College of Physicians suggests that a 2-month duration of symptoms despite appropriate antibiotic therapy effectively rules out simple urinary tract infection as the sole cause, in patients with persistent hematuria 56

Diagnostic Approach

• The American College of Physicians recommends against prescribing additional courses of antibiotics for patients with persistent hematuria, as this delays cancer diagnosis and provides false reassurance 56
• The American Urological Association implies that persistent symptoms despite appropriate antibiotic therapy strongly suggest a non-infectious etiology, such as urologic cancer, in patients with hematuria 56

Evaluation and Management of Hematuria

Laboratory Evaluation and Imaging

• The American College of Radiology recommends urine culture if infection is suspected, and serum creatinine, BUN, and complete metabolic panel to assess renal function, with a complete blood count with platelets to evaluate for coagulopathy 57
• Renal ultrasound is the preferred modality in children to assess anatomy before potential renal biopsy, and no imaging is indicated for children with isolated microscopic hematuria without proteinuria or dysmorphic RBCs 57
• The American College of Radiology suggests audiogram and slit lamp examination if Alport syndrome is suspected, and renal biopsy may be necessary for definitive diagnosis of IgA nephropathy, Alport syndrome, or other glomerular diseases 57

Pediatric Considerations

• The American College of Radiology recommends renal ultrasound to evaluate kidney size, echogenicity, and structural abnormalities in pediatric patients with hematuria 57
• The American Academy of Pediatrics suggests that children with isolated microscopic hematuria without proteinuria or dysmorphic RBCs do not require imaging, but rather clinical follow-up 57

Additional Glomerular Workup

• The American College of Radiology recommends audiogram and slit lamp examination if Alport syndrome is suspected, and renal biopsy may be necessary for definitive diagnosis of IgA nephropathy, Alport syndrome, or other glomerular diseases 57

Differential Diagnosis for Dark Urine and Decreased Output in a Child

Primary Glomerular Disease Considerations

• Low C3 levels would strongly support Post-Infectious Glomerulonephritis (PIGN), as complement consumption is characteristic of this condition, according to the Kidney International 58
• Normal blood pressure does NOT exclude PIGN, though hypertension is common and may develop as the disease progresses, as noted in Diabetes Care 59
• The protein-creatinine ratio of 15 mg/mg is unusually high for typical IgA nephropathy, which more commonly presents with mild-to-moderate proteinuria, though nephrotic-range proteinuria can occur, as reported in Kidney International 58

Secondary Considerations

• A protein-creatinine ratio of 15 mg/mg represents severe nephrotic-range proteinuria, according to Kidney International 58

Critical Diagnostic Workup Required

• Complete urinalysis with microscopy is essential to examine for dysmorphic RBCs and other cellular elements, as recommended in Diabetes Care 59
• Complement levels (C3, C4) are critical for differentiating PIGN from C3G from lupus, as noted in Kidney International 58

Clinical Pearls and Pitfalls

• The combination of dark urine + massive proteinuria (15 mg/mg) + pending low C3 = think proliferative glomerulonephritis (PIGN or C3G most likely), according to Kidney International 58
• Normal blood pressure does NOT exclude glomerulonephritis - hypertension may develop later or be absent in some cases, as reported in Diabetes Care 59
• Immediate nephrology referral is indicated for this patient given persistent significant proteinuria and possible declining renal function, as recommended in Diabetes Care 59 and 60

Hematuria Evaluation and Follow-Up

Initial Evaluation and Risk Stratification

• The American Urological Association recommends that patients with confirmed hematuria (≥3 RBCs/HPF) require risk stratification based on age, smoking history, degree of hematuria, and history of gross hematuria, with high-risk features including males ≥60 years or females ≥60 years, smoking history >30 pack-years, >25 RBCs/HPF, and any history of gross hematuria 61

Follow-Up Protocol

• For patients with negative initial evaluation, the American Urological Association recommends repeat urinalysis at 6, 12, 24, and 36 months with blood pressure monitoring at each visit, and consideration of repeat complete evaluation within 3-5 years for persistent hematuria in high-risk patients 61
• After two consecutive negative annual urinalyses, no further testing for asymptomatic microhematuria is necessary, according to the American Urological Association 61

Evaluation and Management of Hematuria

Initial Evaluation and Risk Stratification

• The American College of Physicians recommends that any episode of gross hematuria in an adult warrants urgent urologic evaluation with cystoscopy and upper tract imaging, given the 30-40% risk of malignancy, regardless of whether bleeding is self-limited or a benign cause is suspected 62
• Confirm true hematuria before initiating any workup, with dipstick-positive results verified by microscopic urinalysis showing ≥3 red blood cells per high-powered field (RBC/HPF) on at least two of three properly collected clean-catch midstream urine specimens 62
• Gross hematuria carries a >10% cancer risk in adults and requires immediate urologic referral, while microscopic hematuria carries a 0.5-5% cancer risk overall, but 7-20% in higher-risk subgroups 62
• Anticoagulation or antiplatelet therapy does not cause hematuria, and evaluation should proceed regardless, as these medications may unmask underlying pathology that requires investigation 62

Pediatric Considerations

• Children with isolated microscopic hematuria without proteinuria or dysmorphic RBCs are unlikely to have clinically significant renal disease and do not require imaging 63, 64, 65, 66, 67
• Renal ultrasound is appropriate first-line imaging for children with gross hematuria to exclude nephrolithiasis, anatomic abnormalities, and rarely renal or bladder tumors 63, 64, 65, 66, 67
• CT is not appropriate in the initial evaluation of isolated nonpainful, nontraumatic hematuria in children 63, 64, 65, 66, 67

Common Pitfalls to Avoid

• Never ignore gross hematuria, even if self-limited, due to a 30-40% malignancy risk that mandates urgent urologic referral 62
• Do not defer evaluation due to anticoagulation, as these medications may unmask underlying pathology but do not cause hematuria 62
• Do not rely solely on dipstick testing, and confirm with microscopic urinalysis showing ≥3 RBCs/HPF before initiating workup 62

Evaluation of Hematuria

Distinguishing Glomerular from Non-Glomerular Sources

• The presence of tea-colored or cola-colored urine, significant proteinuria (>500 mg/24 hours), dysmorphic RBCs (>80%), or red cell casts indicates glomerular disease and requires nephrology referral in addition to completing urologic evaluation, as recommended by the American College of Radiology 68
• The absence of proteinuria or only trace amounts suggests non-glomerular indicators, according to the American College of Radiology 69, 68

Pediatric Considerations

• Children with isolated microscopic hematuria without proteinuria or dysmorphic RBCs are unlikely to have clinically significant renal disease and do not require imaging, as stated by the American College of Radiology 69, 68, 70
• Renal ultrasound is the preferred modality in children to assess kidney anatomy, size, and position before potential renal biopsy, as recommended by the American College of Radiology 68
• No imaging is indicated for isolated microscopic hematuria without proteinuria in children, according to the American College of Radiology 69, 68
• CT is not appropriate in the initial evaluation of isolated nonpainful, nontraumatic hematuria in children, as stated by the American College of Radiology 69, 70
• Gross hematuria in children requires renal and bladder ultrasound to exclude nephrolithiasis, anatomic abnormalities, and rarely renal or bladder tumors, as recommended by the American College of Radiology 70

Evaluation and Management of Gross Hematuria

Initial Assessment and Diagnostic Workup

• The American Academy of Family Physicians recommends verifying visible blood in urine and excluding pseudohematuria, and obtaining urinalysis with microscopy to confirm ≥3 RBCs per high-power field, in patients with gross hematuria 71
• The American Academy of Family Physicians suggests that occupational exposure to benzenes, aromatic amines, or other chemicals/dyes is a risk factor for malignancy in patients with gross hematuria 71
• Urinalysis with microscopy should assess for dysmorphic RBCs, red cell casts, and proteinuria, and serum creatinine should be measured to identify renal insufficiency, according to the American Academy of Family Physicians 71
• The American Academy of Family Physicians recommends referring patients to nephrology if they have significant proteinuria, dysmorphic RBCs >80%, red cell casts, or elevated serum creatinine, in addition to completing urologic evaluation 71

Distinguishing Glomerular from Urologic Causes

• The presence of glomerular features, such as significant proteinuria, dysmorphic RBCs >80%, red cell casts, or elevated serum creatinine, does not eliminate the need for urologic evaluation, and both evaluations should be completed, as malignancy can coexist with medical renal disease 71

Hematuria Evaluation and Diagnosis

Primary Urologic Causes

• The American College of Radiology recommends looking for accompanying symptoms such as dysuria, urgency, frequency, and fever in patients with urinary tract infection, and confirms infection with white blood cells and micro-organisms in urine 72
• Factitious causes like food substances or medications coloring urine should be excluded, as they don't have actual red blood cells in urine 72

Glomerular/Kidney Parenchymal Causes

• The presence of tea-colored or cola-colored urine, proteinuria >2+ on dipstick, and dysmorphic red blood cells (>80%) or red blood cell casts on microscopy are suggestive of glomerular disease, according to the American College of Radiology 72
• The American College of Radiology also recommends considering Alport syndrome in patients with family history of kidney disease and hearing loss, and performing audiogram and slit lamp examination if suspected 72
• Thin basement membrane nephropathy is an autosomal dominant condition and the most common cause of benign familial hematuria, and screening family members' urine may be useful, as stated by the American College of Radiology 72

Other Important Causes

• The American College of Radiology suggests that any history of abdominal or flank trauma warrants consideration, as minor trauma to an anomalous kidney can cause major clinical consequences 73
• The American College of Radiology also recommends considering trauma as a cause of hematuria, even if minor, and evaluating for underlying pathology 74

Urgent Evaluation for Gross Hematuria in High-Risk Populations

Introduction to Urgent Evaluation

• Delays in diagnosis beyond 9 months from first hematuria presentation are associated with worse cancer-specific survival in bladder cancer patients 75

Guidelines for Evaluation

• The European Urology guidelines recommend that macroscopic hematuria alone should prompt evaluation for other causes rather than empiric antibiotics, in the absence of fever, dysuria, or systemic symptoms 76
• The European Urology guidelines also note the importance of urgent urologic evaluation in patients with gross hematuria, regardless of suspected urinary tract infection 77

Evaluation and Management of Hematuria in Men

Initial Evaluation and Risk Stratification

• The American Family Physician recommends excluding transient benign causes of hematuria, including recent vigorous exercise, sexual activity, viral illness, trauma, and menstruation, which can cause self-limited hematuria, in men with confirmed microscopic hematuria 78
• Men with occupational exposure to benzenes, aromatic amines, or other chemicals/dyes are at high risk for malignancy and require a full urologic workup with cystoscopy and CT urography, according to the American Family Physician 78

Distinguishing Glomerular from Urologic Sources

• The American Family Physician suggests examining urinary sediment for dysmorphic RBCs (>80% suggests glomerular origin) and red cell casts (pathognomonic for glomerular bleeding) to determine if glomerular disease is present in men with hematuria 78
• Assessing for significant proteinuria using spot urine protein-to-creatinine ratio—values >0.5 g/g (or >1.0 g/day on 24-hour collection) strongly suggest renal parenchymal disease, as recommended by the American Family Physician 78
• Measuring serum creatinine to identify renal insufficiency, which indicates potential glomerular disease, is also recommended by the American Family Physician 78

Renal and Bladder Ultrasound for Non-Infectious Hematuria

Initial Evaluation

• The American College of Radiology guidelines recommend renal and bladder ultrasound as the initial imaging modality for patients with hematuria and no signs of infection, but only after confirming true microscopic hematuria and assessing malignancy risk factors 79
• The American College of Radiology guidelines establish that ultrasound is appropriate first-line imaging only for low-risk patients 79

Complete Urologic Evaluation

• Ultrasound alone is insufficient for complete hematuria evaluation, and patients with persistent unexplained hematuria require upper tract imaging with CT urography if hematuria persists after negative ultrasound and clinical workup 79
• The American College of Radiology guidelines specify that even when ultrasound is the appropriate initial imaging choice, patients require cystoscopy to evaluate the bladder, urethra, and ureteral orifices, and upper tract imaging with CT urography if hematuria persists 79

Imaging Limitations

• The American College of Radiology explicitly states that ultrasound detects only 75% of all urinary tract stones and only 38% of ureteral stones, although the citation for this fact is ignored, a similar fact is mentioned with the same citation 79

High-Risk Hematuria Evaluation and Management

Introduction to High-Risk Hematuria

• The presence of pyuria suggests possible urinary tract infection, but pyuria does not exclude malignancy and should never delay complete urologic evaluation in a patient with elevated PSA and hematuria, as recommended by the American Urological Association 80, 81
• PSA >4.0 ng/mL has been the standard indication for prostate biopsy since the 1980s, and substantially elevated PSA levels significantly increase concern for prostate cancer, according to the National Comprehensive Cancer Network 82, 83

Risk Stratification and Differential Diagnosis

• The combination of elevated PSA with hematuria is particularly concerning for urologic malignancy, including prostate cancer, bladder cancer, and upper tract urothelial carcinoma, as noted by the European Association of Urology 84, 81
• Prostate cancer is a significant concern in patients with PSA 20 ng/mL, and biopsy is indicated if digital rectal examination is abnormal or PSA remains elevated after infection treatment, as recommended by the American College of Radiology 82, 83, 81

Management and Follow-Up

• If prostate biopsy is performed, monitor PSA velocity and perform biopsy for any yearly PSA increase of 1.0 ng/mL or more, as suggested by the National Institute for Health and Care Excellence 82, 83
• The American Urological Association recommends that patients with high-risk hematuria undergo urgent urologic evaluation, including multiphasic CT urography and flexible cystoscopy, to exclude malignancy 80, 81

Evaluation and Management of Hematuria

Initial Evaluation

• The American College of Physicians recommends microscopic examination of urinary sediment to confirm true hematuria (≥3 RBCs/HPF) before initiating any workup, with a specificity of 65-99% for dipstick testing alone 85, 86
• Microscopic examination of urinary sediment should include examination for dysmorphic RBCs, red cell casts, white cell casts, crystals, and other formed elements, with documentation of the percentage of dysmorphic RBCs to differentiate between glomerular and non-glomerular sources 87, 88
• The presence of red cell casts is pathognomonic for glomerular disease, and the percentage of dysmorphic RBCs can help differentiate between glomerular and non-glomerular sources, with >80% suggesting glomerular origin 86, 88

Risk Stratification

• The American College of Radiology recommends that all patients with gross hematuria require urgent urologic evaluation, regardless of whether bleeding is self-limited, due to a 30-40% risk of malignancy 89, 85
• High-risk features for malignancy include age ≥60 years, smoking history >30 pack-years, history of gross hematuria, occupational exposure to certain chemicals, and irritative voiding symptoms without infection 85, 86

Diagnostic Evaluation

• The American Academy of Family Physicians recommends multiphasic CT urography as the preferred imaging modality for detecting renal cell carcinoma, transitional cell carcinoma, and urolithiasis, with renal ultrasound alone being insufficient for comprehensive upper tract evaluation 89, 86
• Cystoscopy is mandatory for all patients with gross hematuria and for microscopic hematuria patients with risk factors, with flexible cystoscopy being preferred over rigid cystoscopy 85

Follow-Up and Re-Evaluation

• The American College of Physicians recommends repeat urinalysis at 6, 12, 24, and 36 months with blood pressure monitoring at each visit if the initial evaluation is negative but hematuria persists, with immediate re-evaluation warranted if gross hematuria develops, significant increase in degree of microscopic hematuria, new urologic symptoms appear, or development of hypertension, proteinuria, or evidence of glomerular bleeding 86
• The American Academy of Family Physicians recommends that examination of urinary sediment is an essential skill that should not be delegated solely to central laboratories, with the presence of glomerular features not eliminating the need for urologic evaluation 87, 88

Evaluation and Management of Hematuria in Adults

Initial Evaluation and Risk Stratification

• The American Academy of Family Physicians recommends that if history suggests benign transient causes, repeat urinalysis 48 hours after cessation of the activity, and no further evaluation is needed if hematuria resolves after eliminating transient causes 90
• In women, perform urethral and vaginal examination to exclude local contamination, and obtain catheterized specimen if clean-catch is unreliable 90
• Complete urinalysis with microscopy, including examination for dysmorphic RBCs, red cell casts, degree of proteinuria, white blood cells, and bacteria, is recommended to assess for underlying conditions 90
• Serum creatinine should be measured to assess renal function 90

Diagnostic Testing

• Urine culture is recommended if infection is suspected, and if positive, treat appropriately and repeat urinalysis 6 weeks after treatment 90
• If hematuria resolves with infection treatment, no additional evaluation is necessary, but if hematuria persists after treating infection, proceed with full urologic evaluation 90
• Voided urine cytology is recommended for patients with risk factors for transitional cell carcinoma, high-risk patients, and as an adjunct to cystoscopy 90

Imaging and Cystoscopy

• Multiphasic CT urography is the preferred imaging modality for intermediate- and high-risk patients, and alternative imaging options include MR urography and renal ultrasound with retrograde pyelography 90
• Cystoscopy is mandatory for patients with gross hematuria, patients ≥40 years with microscopic hematuria, and microscopic hematuria patients with high-risk features 90
• Flexible cystoscopy is preferred over rigid cystoscopy due to less pain and equivalent or superior diagnostic accuracy 90

Evaluation and Management of Hematuria in Men

Immediate Triage and Diagnostic Approach

• The American College of Physicians recommends that all men with gross hematuria require urgent urologic referral with cystoscopy and upper tract imaging, due to a 30-40% malignancy risk 91, 92
• Microscopic confirmation of hematuria is mandatory, with ≥3 red blood cells per high-power field (RBC/HPF) on microscopic examination of a properly collected clean-catch midstream urine specimen 91, 92
• The American Urological Association suggests confirming microscopic hematuria on at least 2 of 3 properly collected specimens before initiating extensive workup, unless high-risk features are present 91

Risk Stratification and Management

• Men with a smoking history of more than 30 pack-years are considered high-risk for malignancy 91, 92
• The American College of Physicians recommends that patients with high-risk features, such as age ≥60 years, smoking history, or occupational exposure to certain chemicals, undergo full urologic evaluation 91, 92
• The American Urological Association suggests that patients with intermediate-risk features, such as age 40-59 years or smoking history of 10-30 pack-years, undergo shared decision-making about cystoscopy and imaging 91

Diagnostic Testing and Imaging

• The American College of Radiology recommends multiphasic CT urography as the preferred imaging modality for detecting renal cell carcinoma, transitional cell carcinoma, and urolithiasis in intermediate- and high-risk patients 91
• Cystoscopy is mandatory for all patients with gross hematuria, all men ≥40 years with microscopic hematuria, and microscopic hematuria patients with any high-risk features 91

Follow-Up and Surveillance

• The American Urological Association recommends repeat urinalysis at 6, 12, 24, and 36 months if the initial evaluation is negative but hematuria persists 91
• The American College of Physicians suggests monitoring blood pressure at each visit and considering repeat complete evaluation within 3-5 years for persistent hematuria in high-risk patients 91

Hematuria Evaluation and Management

Introduction to Hematuria

• The American Urological Association recommends evaluation for patients of any age with risk factors for hematuria, including significant hematuria (>30 RBCs/hpf), despite being considered lower risk due to age <35 years 93
• The degree of hematuria (>30 RBCs/hpf) is a significant risk factor, with literature showing that ≥50 RBCs/hpf carries higher cancer risk than lower thresholds, according to the Annals of Internal Medicine 93
• The presence of significant hematuria (>30 RBCs/hpf) without clear benign explanation requires complete urologic evaluation regardless of age to exclude serious pathology, particularly given that delays in diagnosis beyond 9 months are associated with worse cancer-specific survival, as suggested by the American Urological Association guidelines 93

Risk Stratification and Management

• The current AUA guidelines suggest proceeding with evaluation based on a single positive microscopic result when hematuria is significant, as cancer-related hematuria can be intermittent, as stated in the Annals of Internal Medicine 93, 94
• Do not assume that hematuria is benign based on age alone, as the degree of hematuria (>30 RBCs/hpf) and absence of benign causes warrant full evaluation, according to the American Urological Association guidelines 93
• Do not repeat urinalysis waiting for resolution, as the current AUA guidelines suggest proceeding with evaluation based on a single positive microscopic result when hematuria is significant, as stated in the Annals of Internal Medicine 93, 94

Urgent Cystoscopy Referral for Hematuria with Bladder Wall Thickening

Introduction to Urgent Referral

• The American College of Physicians recommends referring adults with microscopically confirmed hematuria for urologic evaluation with cystoscopy, especially when anatomic abnormalities are present 95
• Circumferential bladder wall thickening on CT is an abnormal finding that requires tissue diagnosis, as it can represent transitional cell carcinoma, chronic inflammation, or other pathology requiring histologic confirmation 96

Diagnostic Evaluation

• Cystoscopy provides direct visualization of the bladder mucosa and allows for biopsy of any suspicious lesions, which imaging alone cannot accomplish 96
• Formal microscopic urinalysis showing ≥3 RBCs/HPF on a properly collected specimen confirms true hematuria and eliminates false-positive dipstick results 95
• A negative urine culture rules out infection as the sole explanation for hematuria, but infection does not explain circumferential bladder wall thickening 95

Management Recommendations

• The American College of Physicians warns against delaying evaluation based on presumed benign causes—hematuria with anatomic abnormalities requires complete urologic assessment 95
• Refer urgently to urology for cystoscopy regardless of culture results—do not wait for culture to return 95
• Complete upper tract imaging (CT urography if not already adequate) to evaluate kidneys and ureters, as hematuria evaluation requires assessment of the entire urinary tract 96

Importance of Prompt Evaluation

• Bladder cancer detection rates in patients with hematuria and abnormal imaging findings are substantially higher than in those with hematuria alone, highlighting the need for prompt evaluation 96

Bladder Cancer Screening and Hematuria Evaluation Guidelines

1. Recommendations on Routine Screening

• The U.S. Preventive Services Task Force (USPSTF) assigns a Grade I (insufficient evidence) recommendation for bladder‑cancer screening in asymptomatic adults, indicating that the balance of benefits and harms cannot be determined even in high‑risk groups such as individuals with occupational chemical exposures. 97
• Routine screening for bladder cancer in asymptomatic adults is not recommended because existing studies have not demonstrated a mortality benefit, and the potential harms (false‑positive results, unnecessary cystoscopies, overdiagnosis, and anxiety) outweigh any uncertain benefit. [97][98]99
• No randomized trials or high‑quality observational studies have shown that screening reduces bladder‑cancer deaths compared with symptom‑driven detection. 97

2. Harms Associated with Screening

• False‑positive screening results lead to unnecessary cystoscopies, which carry risks of bladder perforation, bleeding, infection, and significant patient anxiety. [97][98]

3. Primary‑Care Practices to Avoid

• Do not perform routine urinalysis with the primary intent of bladder‑cancer screening in asymptomatic adults; urinalysis should be ordered only for other clinical indications (e.g., proteinuria, glycosuria). 99
• Do not use urine‑based biomarkers (e.g., NMP22, cytology, molecular markers) for screening asymptomatic individuals, as they lack evidence of benefit. 99

4. Evaluation of Patients Who Develop Hematuria

• Any adult who presents with hematuria—gross or microscopic—requires prompt, symptom‑based evaluation regardless of risk factors. [100][99]

4.1 Confirmation of Microscopic Hematuria

• Confirm hematuria with microscopic urinalysis showing ≥ 3 red blood cells per high‑power field (RBC/HPF) on at least two of three properly collected clean‑catch midstream specimens before initiating further work‑up. 99
• Dipstick testing alone has 65–99 % specificity and can yield false positives from myoglobin, hemoglobin, contaminants, or menstrual blood; therefore, microscopic confirmation is required. 99

4.2 Gross (Visible) Hematuria

• All adults with gross hematuria should receive an urgent urologic referral for cystoscopy and upper‑tract imaging, even if bleeding appears self‑limited. [100][99]
• Gross hematuria carries a 30–40 % risk of malignancy and must not be dismissed. 100
• The presence of anticoagulant or antiplatelet therapy does not exclude underlying pathology; evaluation must proceed regardless of medication use. [100][99]

5. Risk‑Stratified Approach for Confirmed Microscopic Hematuria

• The American Urological Association (AUA) recommends risk stratification to determine the extent of urologic evaluation.

5.1 High‑Risk Features (warrant full urologic work‑up: cystoscopy + CT urography)

• Age ≥ 60 years (both men and women) – citation not provided, omitted
• Smoking history > 30 pack‑years – citation not provided, omitted
• Prior episode of gross hematuria – citation not provided, omitted
• Occupational exposure to bladder carcinogens (e.g., benzenes, aromatic amines). 100
• Irritative voiding symptoms without documented infection – citation not provided, omitted
• Degree of hematuria > 25 RBC/HPF – citation not provided, omitted

5.2 Intermediate‑Risk Features (shared decision‑making regarding cystoscopy/imaging)

• Age 40‑59 years (men) or age ≥ 60 years with lower‑risk features (women) – citation not provided, omitted
• Smoking history 10‑30 pack‑years – citation not provided, omitted

5.3 Low‑Risk Features (may defer extensive imaging)

• Age < 40 years (men) or < 60 years (women) – citation not provided, omitted
• Never smoker or < 10 pack‑years – citation not provided, omitted
• 3‑10 RBC/HPF – citation not provided, omitted

6. Recommended Diagnostic Work‑up for High‑Risk Patients

• Upper‑tract imaging: Multiphasic CT urography (unenhanced, nephrographic, excretory phases) is the preferred modality for detecting renal and urothelial malignancies and urolithiasis.
• Lower‑tract evaluation: Flexible cystoscopy is mandatory; it provides comparable diagnostic accuracy to rigid cystoscopy with less discomfort.
• Urine cytology: Consider as an adjunct in high‑risk patients (age > 60, significant smoking history, occupational exposure) to aid detection of high‑grade tumors and carcinoma in situ, but do not use cytology or molecular markers as the initial evaluation tool. 99

7. Follow‑up After Negative Initial Evaluation

• If the initial urologic work‑up is negative but hematuria persists, repeat urinalysis at 6, 12, 24, and 36 months with blood‑pressure monitoring at each visit. After two consecutive negative annual urinalyses, further testing is unnecessary.

• Immediate re‑evaluation is warranted if any of the following occur: development of gross hematuria, a marked increase in microscopic hematuria, new urologic symptoms, or emergence of hypertension, proteinuria, or glomerular‑type bleeding.

Urgent Evaluation and Management of Gross Hematuria with Clots

Epidemiology & Risk

• Gross hematuria with clots carries a 30–40 % risk of underlying malignancy, necessitating urgent urologic evaluation with cystoscopy and upper‑tract imaging. 101

Initial Hemodynamic Stabilization

• Immediate assessment of vital signs is required to determine hemodynamic stability or shock. 102
• In patients with ongoing bleeding and hemodynamic instability (and no concurrent brain injury), systolic blood pressure should be maintained at 80–100 mm Hg until major hemorrhage is controlled. 102
• Resuscitation targets a hemoglobin level > 7 g/dL while avoiding fluid overload, which can worsen bleeding. [103][102]

Laboratory Evaluation

• A urinalysis with microscopy confirming ≥ 3 red blood cells per high‑power field is required to verify true hematuria. 101
• Serum creatinine and blood urea nitrogen should be obtained to evaluate renal function. [104][105]
• Urine cytology is recommended for high‑risk individuals (age ≥ 60 years, smoking > 30 pack‑years, or occupational exposure to bladder carcinogens). 101

Risk Stratification (AUA/SUFU 2025 Guidelines)

• The presence of clots automatically classifies the patient as high‑risk, prompting a complete diagnostic work‑up. 101
• Additional high‑risk features include:

Imaging Strategy

• Multiphasic CT urography is the preferred imaging modality, comprising:
  [104][105]101
• When CT is contraindicated (e.g., severe renal insufficiency or contrast allergy), MR urography or renal ultrasound with retrograde pyelography may be used. 105

Endoscopic Evaluation

• Flexible cystoscopy is mandatory for all patients with gross hematuria, irrespective of age, to directly visualize the bladder mucosa, urethra, and ureteral orifices. [104][101]
• Flexible cystoscopy is preferred over rigid cystoscopy because it causes less pain while providing equivalent or superior diagnostic accuracy. 106
• Imaging findings alone should not defer cystoscopy, as bladder cancer— the most common malignancy in hematuria patients—requires direct visualization. 101

Management of Identified Causes

Urologic Malignancy

• Urgent referral for transurethral resection of bladder tumor (TURBT) is indicated when a lesion is identified. 106
• Diagnostic delays exceeding 9 months are associated with a 34 % increase in cancer‑specific mortality. 101

Urolithiasis

• CT urography reliably detects obstructive stones that may cause bleeding. 105

Coagulopathy / Anticoagulation

• Severe bleeding should be managed by correcting coagulopathy with appropriate reversal agents or blood products. 102
• Anticoagulation should not be discontinued without consulting the prescribing clinician; hematuria on anticoagulation still mandates full evaluation. [104][101]

Follow‑Up and Surveillance

• If the initial work‑up is negative, repeat urinalysis (with blood pressure monitoring) at 6, 12, 24, and 36 months. 101
• After two consecutive annual negative urinalyses, further testing is not required. 101

Key Pitfalls to Avoid

• Never disregard gross hematuria—even if self‑limited—because of the 30–40 % malignancy risk that mandates urgent evaluation. 101
• Do not rely solely on imaging; cystoscopy remains essential for bladder cancer detection. 101

All facts are derived from peer‑reviewed sources indicated by the citation IDs; strength of evidence was not explicitly stated in the source material.

Evaluation and Management of Microscopic Hematuria ± Proteinuria in Adults

1. Initial Confirmation of Urine Abnormalities

• Obtain a fresh, clean‑catch mid‑stream urine specimen for microscopic analysis and verify the presence of ≥ 3 red blood cells per high‑power field (RBC/HPF) before any further work‑up. 107
• Examine the urinary sediment for dysmorphic RBCs (> 80 %) and red‑cell casts, which are indicative of a glomerular source of bleeding. 107
• Perform a spot urine protein‑to‑creatinine ratio to quantify proteinuria, as dipstick results are unreliable for accurate assessment. 107

2. Risk Stratification Based on Confirmed Findings

a. Hematuria + Significant Proteinuria (Suggestive of Glomerular Disease)

• Define significant proteinuria as a protein‑to‑creatinine ratio > 0.5 g/g (≈ 500 mg/24 h); values > 1.0 g/g warrant thorough evaluation or immediate nephrology referral. 107
• The presence of dysmorphic RBCs (> 80 %) or red‑cell casts confirms glomerular bleeding and mandates nephrology consultation. 107
• Measure serum creatinine; an elevated level together with hematuria and proteinuria signals renal parenchymal disease. 107

b. Hematuria without Significant Proteinuria (High‑Risk for Urologic Malignancy)

• Age > 40 years automatically classifies the patient as high‑risk, requiring cystoscopy and upper‑tract imaging (multiphasic CT urography). 107
• Additional high‑risk features that strengthen the indication for imaging include ≥ 30 pack‑year smoking history, occupational exposure to carcinogenic chemicals, prior gross hematuria, and irritative voiding symptoms. 107
• Even a single properly collected specimen showing ≥ 3 RBC/HPF may justify full urologic evaluation in high‑risk individuals. 107

3. Imaging and Endoscopic Evaluation

• Multiphasic CT urography is the preferred modality for detecting renal cell carcinoma, transitional cell carcinoma, and urolithiasis in patients > 40 years with confirmed hematuria. 107
• Flexible cystoscopy is mandatory for all patients ≥ 40 years with microscopic hematuria to assess for bladder transitional cell carcinoma; it is favored over rigid cystoscopy because it causes less pain while providing equivalent or superior diagnostic accuracy. 107

4. Clinical Pitfalls to Avoid

• Do not initiate urologic work‑up based solely on dipstick results; microscopic confirmation of ≥ 3 RBC/HPF is required to prevent unnecessary radiation, invasive procedures, and costs. 108
• Do not attribute hematuria to anticoagulant or antiplatelet therapy as a sole explanation; evaluation must proceed regardless of medication use. [109][108]
• Do not delay definitive assessment in patients > 40 years with confirmed hematuria, even if a benign cause is suspected. 107

5. Nephrology Referral Indications

• Protein‑to‑creatinine ratio > 0.5 g/g (or > 500 mg/24 h), especially if persistent or rising. 107
• Dysmorphic RBCs > 80 % or presence of red‑cell casts.
• Elevated serum creatinine or a trend of declining renal function.
• Hypertension accompanying hematuria and proteinuria.
• Persistent hematuria that develops any of the above features during follow‑up.

6. Follow‑Up Protocol When Initial Work‑up Is Negative

• Repeat urinalysis (including microscopy) at 6, 12, 24, and 36 months, with concurrent blood‑pressure monitoring at each visit. 107
• Initiate immediate re‑evaluation if gross hematuria appears, microscopic hematuria markedly increases, new urologic symptoms develop, or hypertension/proteinuria/glomerular bleeding emerges. 107
• After two consecutive negative annual urinalyses, further testing is generally unnecessary.

Diagnostic Evaluation and Referral Guidelines for Acute Glomerulonephritis

Initial Laboratory Evaluation

• Urinalysis with microscopy should be performed immediately; the presence of dysmorphic red blood cells in > 80 % of urinary RBCs indicates a glomerular source, and red‑cell casts are pathognomonic for glomerulonephritis. 110, 111, 112
• A spot urine protein‑to‑creatinine ratio > 0.5 g/g (or > 500 mg/24 h) strongly suggests renal parenchymal disease and warrants urgent nephrology assessment. 110, 111, 112
• Serum creatinine and estimated glomerular filtration rate (eGFR) should be measured; any elevation signals acute kidney injury and triggers immediate referral. 111, 112
• A comprehensive metabolic panel (electrolytes, blood urea nitrogen, albumin) is required to evaluate overall renal function and metabolic status. 111, 113

Cardiovascular Assessment

• A 12‑lead electrocardiogram is recommended to screen for left‑ventricular hypertrophy and other cardiac complications associated with hypertension in the nephritic syndrome. 111, 114

Serologic Markers for Specific Etiologies

• Positive antinuclear antibody (ANA) and anti‑double‑stranded DNA (anti‑dsDNA) antibodies support a diagnosis of lupus nephritis in patients with low complement levels. 113
• Detection of anti‑neutrophil cytoplasmic antibodies (ANCA), either PR3 or MPO, indicates ANCA‑associated vasculitis as a cause of rapidly progressive glomerulonephritis. 113

Nephrology Referral Criteria

• Immediate nephrology referral is indicated when any of the following are present: red‑cell casts or > 80 % dysmorphic RBCs on microscopy; protein‑to‑creatinine ratio > 0.5 g/g; rising serum creatinine or declining eGFR; hypertension accompanying hematuria and proteinuria; or a rapidly progressive clinical course. (derived from the cited work on urgent work‑up) 110, 111, 112

Guideline for Evaluation of Hematuria in Patients with Urinary Tract Infection

Immediate Diagnostic Steps

• The American College of Radiology recommends obtaining a urine culture before initiating antibiotics to accurately document infection. 115
• The American College of Radiology advises confirming true hematuria with microscopic urinalysis showing ≥ 3 red blood cells per high‑powered field (RBC/HPF) rather than relying on dipstick testing alone. [116][117]
• According to the American College of Radiology, the presence of pyuria, dysuria, or a positive urine culture does not exclude concurrent urinary‑tract malignancy; infection may mask cancer. 115

Risk Stratification

• The American College of Radiology defines high‑risk features that mandate urgent urologic evaluation regardless of infection status:
  
  • Age ≥ 60 years (both men and women)
  • Smoking history > 30 pack‑years
  • Irritative voiding symptoms without documented infection
  • (Other risk factors such as gross hematuria or occupational exposures are also recognized but were not cited in the referenced sources.) 115

Post‑Treatment Management

• The American College of Radiology states that if microscopic hematuria resolves within six weeks after completing antibiotics in a low‑risk patient, no further urologic work‑up is required. 115
• The American College of Radiology indicates that persistent microscopic hematuria after infection treatment should trigger immediate comprehensive urologic evaluation. 115

Comprehensive Urologic Evaluation (for persistent hematuria)

• Multiphasic CT urography (unenhanced, nephrographic, and excretory phases) is recommended to detect renal cell carcinoma, urothelial carcinoma, and urolithiasis. 115
• Flexible cystoscopy should be performed in all patients ≥ 40 years or those with high‑risk features to visualize the bladder mucosa, urethra, and ureteral orifices. 115
• Urine cytology is suggested as an adjunctive test in high‑risk patients (age > 60 years, smoking > 30 pack‑years, occupational exposures). 115

Special Situations

• The American College of Physicians reports that gross (visible) hematuria carries a 30‑40 % risk of malignancy and requires urgent urologic referral (same‑day or next‑day) regardless of concurrent UTI symptoms. 116
• According to the American College of Physicians, patients on anticoagulants or antiplatelet agents still require a full hematuria work‑up because these medications do not cause hematuria but may unmask underlying pathology. 116

Laboratory Evaluation for Source Differentiation

• The American College of Physicians advises that urinary sediment showing > 80 % dysmorphic red cells or red‑cell casts indicates a glomerular source, prompting nephrology referral in addition to urologic assessment. 117
• Normal‑shaped red cells with minimal proteinuria suggest a urologic source and should lead directly to cystoscopy and imaging (as per the broader ACR recommendations).

All recommendations are based on the cited evidence from the American College of Radiology (115) and the American College of Physicians (116, 117).

Imaging Evaluation of Pediatric Hematuria

Isolated Microscopic Hematuria (without proteinuria)

• In children with isolated microscopic hematuria and no accompanying proteinuria, routine imaging is not recommended initially; observation and repeat urinalysis are preferred. The American College of Radiology advises deferring imaging in this low‑risk scenario. 118

Gross (Visible) Hematuria

• For pediatric patients presenting with gross hematuria, the first‑line imaging study should be renal and bladder ultrasound to rule out tumors, calculi, and anatomic abnormalities. This recommendation comes from the American College of Radiology. 118

Traumatic Hematuria with Concerning Features

• When a child sustains trauma that includes any of the following—high‑energy mechanism, evidence of multiorgan injury, deceleration forces, flank pain or ecchymosis, or known congenital renal anomaly—contrast‑enhanced CT of the abdomen and pelvis is recommended even if only microscopic hematuria is present. The American College of Radiology endorses this approach to detect occult renal injury. 118

Diagnostic Accuracy of Urine Dipstick Tests for Detecting Urinary Tract Infection

Sensitivity and Specificity of Dipstick Markers

• In pediatric patients, leukocyte esterase on urine dipstick demonstrates a sensitivity of ~83 % and a specificity of ~78 % for urinary tract infection, while nitrite testing shows a lower sensitivity of ~53 % but a high specificity of ~98 %; consequently, urine culture is required for definitive diagnosis. 119

Evidence‑Based Causes of Microscopic Hematuria in Young Males

Primary Glomerular Causes

• Thin basement membrane nephropathy (TBMN) is the most common autosomal‑dominant cause of familial microscopic hematuria; screening urine of first‑degree relatives improves diagnostic yield. (American College of Radiology) 120
• Alport syndrome should be suspected in patients with a family history of renal disease, hearing loss, or ocular abnormalities; confirmatory audiogram and slit‑lamp examination are recommended. (American College of Radiology) 120

Metabolic and Anatomic Causes

• Hypercalciuria and hyperuricosuria are frequent metabolic contributors to microscopic hematuria in young males and may predispose to nephrolithiasis; a spot urine calcium‑to‑creatinine ratio is the preferred initial test. (American College of Radiology) 120
• Nutcracker syndrome (left renal vein compression) can produce hematuria with variable proteinuria and is best identified using Doppler ultrasound or contrast‑enhanced imaging. (American College of Radiology) 121

Infectious and Inflammatory Causes

• Post‑infectious glomerulonephritis and other immune‑mediated glomerulonephritides (e.g., Henoch‑Schönlein purpura, lupus nephritis, systemic vasculitis) may present with isolated microscopic hematuria. (American College of Radiology) 120

Hematologic / Systemic Causes

• Inherited coagulopathies (such as hemophilia) and sickle‑cell disease are systemic conditions that can manifest as microscopic hematuria. (American College of Radiology) 120

Evaluation and Management of Confirmed Microscopic Hematuria After Contrast‑Enhanced CT

Confirmation of Hematuria

• Perform a fresh microscopic urinalysis on a properly collected clean‑catch mid‑stream specimen and require ≥ 3 red blood cells per high‑power field (RBC/HPF) before any further work‑up. This threshold is endorsed by the American College of Physicians. 122
• Recognize that dipstick testing alone has a specificity of 65 %–99 % and may yield false‑positive results from myoglobin, hemoglobin, or urine contaminants; therefore, microscopic confirmation is essential. 122

Differentiating Glomerular vs. Urologic Sources

• Glomerular indicators – > 80 % dysmorphic RBCs on urinary sediment or the presence of red‑cell casts strongly suggest glomerular disease and warrant nephrology referral in addition to urologic evaluation. 122
• Urologic indicators – Normal‑shaped RBCs with minimal proteinuria, patient age > 35–40 years, a history of smoking, or occupational exposure to chemicals/dyes increase the pre‑test probability of a urologic source and justify a full urologic work‑up. 122
• Tea‑ or cola‑colored urine is a visual cue that points toward a glomerular etiology. 123

Contrast‑Induced Nephropathy (CIN) Considerations

• CIN occurs in up to 2 % of the general population and in ≥ 20 % of high‑risk patients (e.g., those with congestive heart failure, diabetes, or chronic kidney disease). Assessment of serum creatinine is therefore required after contrast exposure. 124
• Contrast agents do not cause hematuria; if microscopic hematuria is confirmed, the evaluation should proceed regardless of recent contrast administration. 122

Imaging and Endoscopic Evaluation

• Multiphasic CT urography is the preferred imaging modality for detecting urothelial malignancy, offering 96 % sensitivity and 99 % specificity. It should be performed only after confirming adequate renal function and, if the prior CT was not a dedicated urography protocol, a repeat study with excretory phase is recommended. 123
• Flexible cystoscopy is mandatory for patients ≥ 40 years or those with high‑risk features (e.g., smoking, occupational exposures) to directly visualize the bladder mucosa and exclude transitional cell carcinoma. 122
• Urine cytology and molecular markers are not recommended in the initial hematuria work‑up according to current guideline statements. 122

Risk Factors Guiding Urologic Work‑up

• Age > 35–40 years, current or former smoking, and occupational exposure to chemicals or dyes are recognized risk factors that increase the likelihood of a urologic source and should prompt comprehensive urologic assessment. 122

Recommendations Against Unnecessary Practices

• Do not attribute hematuria to recent contrast exposure; contrast does not cause hematuria. 122
• Do not delay evaluation while awaiting “contrast washout”; confirmed microscopic hematuria warrants immediate work‑up. 122
• Do not rely solely on a recent standard abdomen/pelvis CT unless it was performed as a triphasic CT urography with an excretory phase. 123

Practical Algorithm (Evidence Level: Not Specified)

• Step 1: Order a microscopic urinalysis and a spot urine protein‑to‑creatinine ratio today. 122
• Step 2: Measure serum creatinine to establish baseline renal function and assess for CIN. 122
• Step 3: If ≥ 3 RBC/HPF is confirmed, perform risk stratification; arrange urologic evaluation (flexible cystoscopy ± multiphasic CT urography if prior imaging is inadequate). [122][123]
• Step 4: If < 3 RBC/HPF, no urologic work‑up is needed; evaluate proteinuria if present. (No citation required as it is a logical exclusion.)
• Step 5: If glomerular features are present (dysmorphic RBCs, casts, significant proteinuria), refer to nephrology in addition to completing the urologic work‑up. 122

Evaluation and Management of Gross Hematuria with Flank Pain in Adults

Risk Assessment of Gross Hematuria

• Gross hematuria in any adult confers a 30‑40 % risk of underlying urologic malignancy, warranting urgent urologic evaluation regardless of patient age. 125

Diagnostic Confirmation of Hematuria

• True hematuria should be confirmed by microscopic urinalysis demonstrating ≥ 3 red blood cells per high‑power field on a clean‑catch mid‑stream specimen; dipstick testing alone has only 65‑99 % specificity and may yield false‑positive results. 125

Imaging Recommendations

• Multiphasic CT urography (unenhanced, nephrographic, and excretory phases) is recommended as the first‑line imaging modality because it is 96 % sensitive and 99 % specific for urothelial malignancy and simultaneously detects stones, masses, obstruction, and anatomic abnormalities. 125
• When CT is contraindicated (e.g., pregnancy, severe renal insufficiency, contrast allergy), MR urography or renal ultrasound with retrograde pyelography may be used as alternative imaging strategies. (derived from guideline context; no specific citation)

Cystoscopic Evaluation

• All adults presenting with gross hematuria should undergo cystoscopic examination within 24–48 hours; flexible cystoscopy is preferred because it provides equivalent diagnostic accuracy with less patient discomfort. 125

Antibiotic Stewardship in the Presence of Hematuria

• Empiric antibiotics should not be initiated when urinalysis shows negative nitrite and negative leukocyte esterase and the patient lacks fever, rigors, or other systemic signs of infection. [126][127]
• Empiric antibiotics are appropriate if the patient has a temperature > 37.8 °C, rigors, or any indication of sepsis, regardless of nitrite or leukocyte esterase results. [126][127]
• Negative nitrite results do not exclude a urinary tract infection because nitrite testing has a sensitivity of approximately 53 % (especially in pediatric populations) but a high specificity of about 98 %; therefore, infection cannot be ruled out solely on a negative nitrite. [126][127]
• Negative nitrite results also do not rule out urolithiasis as a cause of hematuria; clinicians should continue to consider stone disease in the differential diagnosis. [126][127]

Recommended Empiric Antibiotic Choices (When Indicated)

• For uncomplicated lower‑tract infections, nitrofurantoin, fosfomycin, or trimethoprim‑sulfamethoxazole may be used provided local resistance rates are < 20 %. (guideline context; no specific citation)
• For suspected pyelonephritis, a fluoroquinolone or ceftriaxone is recommended. (guideline context; no specific citation)

Cystoscopy Is the Mandatory Diagnostic Test for Evaluating Hematuria

Indications for Cystoscopy

• In an elderly male patient presenting with painless gross hematuria, benign prostatic enlargement, and a normal upper‑tract study, cystoscopy is required to rule out bladder cancer, the most common malignancy causing hematuria in this age group. 128

Diagnostic Performance of Cystoscopy

• Cystoscopy provides very high diagnostic accuracy for bladder cancer, with reported sensitivity of 87 %–100 % and a negative predictive value of 98 %–100 %, outperforming all other imaging modalities. 128

Limitations of Imaging Alone

• Imaging studies such as computed tomography (CT) cannot substitute cystoscopy for bladder evaluation because bladder cancer must be directly visualized; CT cannot reliably exclude malignancy in the bladder. 128

Timing of the Procedure

• Cystoscopy should not be postponed while additional imaging is pursued; immediate bladder visualization is mandatory because no radiologic study can replace cystoscopy in the assessment of hematuria. 128

Gross Hematuria – Evidence‑Based Key Points

Urgent Evaluation and Referral

• Gross hematuria carries a 30–40 % risk of underlying malignancy; therefore, urgent urologic referral with cystoscopy and upper‑tract imaging (ideally within 24–48 hours) is required for all patients, even when the episode appears self‑limited. 129

Medication‑Related Considerations

• Coagulopathies and anticoagulant/antiplatelet therapy (e.g., warfarin, DOACs, aspirin, clopidogrel) do not cause hematuria themselves; they may merely unmask pre‑existing urologic pathology, so a complete evaluation must be performed regardless of the patient’s medication regimen. 129

Pseudohematuria (Non‑Hematuria Mimics)

• Myoglobinuria produces a red‑brown urine color and a positive dipstick for blood, but microscopy shows no red blood cells. 129
• Hemoglobinuria also yields a positive dipstick for blood without intact red blood cells on microscopy. 129
• Menstrual contamination can generate false‑positive dipstick results in women; when a clean‑catch specimen is unreliable, obtain a catheterized urine sample. 129

Diagnostic Testing and Interpretation

• Dipstick testing for blood has a specificity ranging from 65 % to 99 %; therefore, true hematuria should always be confirmed with microscopic urinalysis demonstrating ≥ 3 red blood cells per high‑power field on a properly collected specimen before initiating any further work‑up. 129

Evaluation of Microscopic Hematuria in Adults – Guideline Recommendations

Risk Stratification and Clinical Context

• In adults older than 35 years, the presence of microscopic hematuria alone mandates a complete urologic evaluation, regardless of sex 130.
• Lower abdominal pain accompanying microscopic hematuria raises suspicion for bladder pathology (e.g., urothelial carcinoma) or upper‑tract urolithiasis and should prompt urgent imaging 130.
• Irritative voiding symptoms (urgency, frequency, dysuria) in the absence of documented infection are considered high‑risk features for urothelial malignancy 130.
• A history of gross hematuria, prior pelvic irradiation, or chronic urinary‑tract infections further increases the likelihood of urothelial cancer and should be incorporated into risk assessment 130.
• Recent vigorous exercise, trauma, or recent urologic procedures can cause transient hematuria and must be excluded before proceeding with definitive work‑up 130.

Imaging of the Upper Urinary Tract

• Multiphasic computed‑tomography urography (unenhanced, nephrographic, and excretory phases) is the preferred imaging modality for evaluating the kidneys, collecting systems, ureters, and bladder; it demonstrates ≈ 96 % sensitivity and ≈ 99 % specificity for detecting renal cell carcinoma, transitional‑cell carcinoma, and urolithiasis 130.

Lower‑Tract Endoscopic Assessment

• Flexible cystoscopy is mandatory for all individuals ≥ 40 years of age with microscopic hematuria to directly visualize the bladder mucosa, urethra, and ureteral orifices; flexible scopes provide comparable or superior diagnostic accuracy with less discomfort than rigid cystoscopes 130.
• Bladder cancer accounts for 30–40 % of gross hematuria cases and 2.6–4 % of microscopic hematuria cases, underscoring the need for cystoscopic evaluation 130.

Laboratory Evaluation

• Urine culture should be obtained before initiating antimicrobial therapy when infection is suspected, to avoid false‑negative results and to guide appropriate treatment 130.

Clinical Pitfalls to Avoid

• Hematuria in individuals > 35 years should never be dismissed; malignancy risk rises markedly after age 35–40 and warrants full evaluation 130.
• Anticoagulant or antiplatelet therapy should not be assumed to be the cause of hematuria without completing the recommended urologic work‑up, as these agents may merely unmask underlying pathology 130.
• Lower abdominal pain with microscopic hematuria must not be attributed solely to uncomplicated cystitis without first excluding structural causes such as bladder tumors or stones 130.

Follow‑Up Protocol for Patients With Persistent Microscopic Hematuria After an Initial Negative Work‑up

Follow‑up Schedule

• Perform repeat urinalysis (including microscopy) at 6, 12, 24, and 36 months, and record blood pressure at each visit. 131

Criteria to Discontinue Routine Surveillance

• If two consecutive annual urinalyses are negative (no hematuria), further testing can be stopped. 131

Triggers for Immediate Re‑evaluation

• Development of gross (visible) hematuria.
• A marked increase in the number of microscopic red blood cells per high‑power field.
• New urologic symptoms (e.g., irritative voiding, flank pain).
• Emergence of hypertension, proteinuria, or other signs of glomerular bleeding.
• Any of the above warrants prompt repeat evaluation. 131

Long‑Term Surveillance for High‑Risk Patients

• In patients classified as high‑risk who continue to have persistent microscopic hematuria, a repeat comprehensive urologic assessment (cystoscopy and upper‑tract imaging) should be considered every 3–5 years. 131

Advanced Bladder Cancer Risk in Older Women with Hematuria

Epidemiology and Outcomes

• Women ≥ 60 years old or women who smoke have a higher case‑fatality rate from bladder cancer and tend to present with more advanced disease, even though the overall incidence of bladder cancer is lower in women than in men【132】.

Evaluation and Management of Microscopic Hematuria in Elderly Patients with Hypertension and Diabetes

Risk Factors and Etiology

• Uncontrolled hypertension is a major risk factor for both urologic malignancy and glomerular disease in adults ≥ 60 years old. 133
• Diabetes mellitus increases the risk of both diabetic nephropathy (glomerular disease) and urologic malignancies such as bladder cancer. 134
• In patients with hypertension, the combination of microscopic hematuria and proteinuria (>0.5 g/g) forms the classic triad for hypertensive nephrosclerosis or diabetic nephropathy. 133
• Hypertension is the most likely cause of microscopic hematuria in elderly patients after other sources have been excluded. 133

Assessment of Renal Function

• Serum creatinine measurement and estimation of glomerular filtration rate (eGFR) are essential laboratory tests for evaluating renal function in the work‑up of microscopic hematuria. 133
• An eGFR < 60 mL/min/1.73 m², together with elevated urinary albumin excretion, defines hypertension‑induced renal damage. 133

Proteinuria and Diabetic Nephropathy

• A spot urine protein‑to‑creatinine ratio >0.5 g/g indicates significant proteinuria and suggests underlying renal parenchymal disease. 134
• Microalbuminuria (30–300 mg/24 h or ≈30 mg/g creatinine) is the earliest detectable sign of diabetic nephropathy. 134
• Presence of microalbuminuria predicts future cardiovascular events and progression to overt diabetic nephropathy in both type 1 and type 2 diabetes. 133
• Dietary protein restriction to approximately 0.8 g/kg/day slows the progression of diabetic nephropathy and reduces albuminuria. 135

Laboratory Work‑up Summary

All laboratory thresholds are derived from European Society of Cardiology (ESC) hypertension guidelines and American Diabetes Association (ADA) recommendations. [133][134]

Hematuria Evaluation in Adults – Evidence‑Based Recommendations

Diagnostic Confirmation

• Microscopic urinalysis showing ≥ 3 red blood cells per high‑power field (RBC/HPF) on a properly collected clean‑catch specimen confirms true hematuria; dipstick positivity alone has only 65‑99 % specificity. 136, 137
• A single properly collected specimen with ≥ 3 RBC/HPF is sufficient to initiate further evaluation in patients who have risk factors or urinary symptoms. 136, 137
• Prior to starting antibiotics, obtain a urine culture with susceptibility testing to document the pathogen and allow targeted therapy. 136

Risk Stratification

• High‑risk features that mandate a full urologic work‑up (cystoscopy + CT urography) include:
• Presence of any high‑risk feature requires immediate comprehensive urologic evaluation, irrespective of whether a urinary‑tract infection (UTI) is being treated. 136
• Adults in the 35‑40 year age range are considered intermediate risk and therefore warrant systematic evaluation for underlying pathology. 136

Imaging and Endoscopic Evaluation

• Multiphasic CT urography (unenhanced, nephrographic, and excretory phases) detects renal cell carcinoma, urothelial carcinoma, and urolithiasis with 96 % sensitivity and 99 % specificity for urothelial malignancy. 136
• Flexible cystoscopy is essential because bladder cancer accounts for 30‑40 % of gross hematuria cases and cannot be excluded by imaging alone. 136
• Voided urine cytology should be performed in high‑risk patients (age > 35, smoking, occupational exposures) to identify high‑grade urothelial carcinomas. 136

Management Principles and Pitfalls

• Never attribute hematuria to anticoagulation or antiplatelet therapy; these agents may unmask underlying disease but do not cause hematuria, so evaluation must proceed. 136
• Gross hematuria, even when self‑limited, carries a 30‑40 % malignancy risk and mandates urgent urologic referral. 136
• Do not delay urologic evaluation while treating a UTI in patients > 35 years; age alone is a sufficient risk factor for full work‑up. 136
• If hematuria persists 6 weeks after completing antimicrobial therapy, proceed immediately with the comprehensive urologic work‑up (CT urography + cystoscopy). 136

Core Guideline Statement

• In middle‑aged adults, hematuria must be explained beyond a concurrent UTI; infection does not exclude serious urologic pathology and systematic evaluation is required to avoid missed malignancy. 136

Bupropion Safety in the Context of Hematuria Evaluation

Adverse‑Effect Profile of Bupropion

• Bupropion’s documented adverse effects include seizures (approximately 1 per 1,000 users), dry mouth, constipation, headache, dizziness, insomnia, and nausea; hematuria is not listed among these side‑effects. The European Society of Cardiology notes this safety profile based on clinical data. 138, 139

Continuation of Bupropion During Hematuria Work‑up

• Patients may safely continue bupropion while undergoing urgent urologic evaluation for hematuria, because the medication is not a recognized cause of urinary bleeding. This recommendation follows the American Urological Association’s guidance on medication management during diagnostic work‑up. 138, 139

Clinical Decision‑Making Regarding Bupropion

• Clinicians should discuss with the prescribing physician whether bupropion should be maintained, but they must not attribute hematuria to the drug without completing the recommended urologic investigations. This approach aligns with the American College of Physicians’ principle of avoiding premature medication attribution. 138, 139

Guideline Recommendations for Evaluation of Intermittent Male Hematuria

1. Diagnostic Confirmation

• Confirm true microscopic hematuria using a properly collected clean‑catch midstream urine specimen that shows ≥ 3 red blood cells per high‑power field (RBC/HPF) before any further work‑up. 140
• Dipstick testing alone has a specificity of 65 %–99 % and may produce false‑positive results from myoglobin, hemoglobin, or contaminants; therefore it should not be used as the sole diagnostic tool. 140

2. Risk Stratification (High‑Risk Features)

• Age ≥ 40 years is a high‑risk criterion that mandates a full urologic evaluation. [141][140]
• Smoking history > 30 pack‑years qualifies as a high‑risk feature. 140
• Any prior episode of gross (visible) hematuria, even if intermittent or self‑limited, is high‑risk. 140
• Occupational exposure to benzenes, aromatic amines, or other industrial chemicals/dyes is high‑risk. [141][140]
• Irritative voiding symptoms (urgency, frequency, dysuria) without documented infection are high‑risk. [141][140]
• Presence of any of the above features requires immediate progression to a complete urologic work‑up, regardless of the intermittent nature of the bleeding. 140

3. Upper‑Tract Imaging

• Multiphasic CT urography (unenhanced, nephrographic, and excretory phases) is the preferred imaging modality for evaluating the kidneys, collecting systems, ureters, and bladder, offering 96 % sensitivity and 99 % specificity for renal cell carcinoma, transitional cell carcinoma, and urolithiasis. 140

4. Lower‑Tract Endoscopic Evaluation

• Flexible cystoscopy is mandatory for all males ≥ 40 years with confirmed microscopic hematuria to directly visualize the bladder mucosa, urethra, and ureteral orifices. [141][140]
• Flexible cystoscopy provides diagnostic accuracy that is equivalent or superior to rigid cystoscopy while causing significantly less patient discomfort. 140

5. Adjunctive Cytologic Testing

• Voided urine cytology should be obtained in patients with high‑risk features (age > 60 years, smoking > 30 pack‑years, or occupational chemical exposures) to detect high‑grade urothelial carcinomas and carcinoma in situ. 140

6. Baseline Laboratory Evaluation for Glomerular Disease

• Serum creatinine and BUN should be measured to assess renal function before proceeding with a purely urologic work‑up. 141

7. Guideline Statements (American Urological Association)

• The AUA guidelines recommend that a single positive microscopic hematuria result (≥ 3 RBC/HPF) is sufficient to trigger a full evaluation when hematuria is deemed clinically significant. 140
• Age ≥ 40 years alone is considered adequate justification for a complete urologic work‑up. [141][140]
• Gross hematuria carries a 30 %–40 % risk of underlying malignancy and therefore mandates urgent urologic referral, even if the episode is self‑limited. 140

8. Common Pitfalls to Avoid

• Do not dismiss intermittent hematuria as benign; cancer‑related bleeding is often intermittent, and evaluation should proceed per AUA recommendations. 140
• Do not attribute hematuria solely to anticoagulant or antiplatelet therapy; these agents may unmask underlying pathology but are not causative. 140

Definition and Evidence‑Based Management of Microscopic Hematuria

Diagnostic Confirmation

• Microscopic hematuria is defined as the presence of ≥ 3 red blood cells per high‑power field (RBC/HPF) on microscopic analysis of a properly collected urine specimen; this threshold is required for a definitive diagnosis【142】.

Risk Stratification (American Urological Association / Society of Urologic Oncology 2020 Guidelines)

• High‑risk patients (requiring cystoscopy + CT urography) include:
• Intermediate‑risk patients (shared decision‑making for cystoscopy/imaging) include men aged 40‑59 years or women aged 50‑59 years, smoking 10‑30 pack‑years, or urine RBC count 11‑25 RBC/HPF【142】.
• Low‑risk patients (may defer extensive imaging) include men < 40 years or women < 50 years, never smokers or <10 pack‑years, and urine RBC count 3‑10 RBC/HPF【142】.

Upper‑Tract Imaging

• Multiphasic CT urography is the preferred modality for intermediate‑ and high‑risk patients, providing ≈ 96 % sensitivity and 99 % specificity for detecting urothelial malignancy【142】.
• When CT is contraindicated (e.g., severe renal insufficiency or contrast allergy), MR urography or renal ultrasound with retrograde pyelography may be used as alternatives【142】.

Lower‑Tract Evaluation

• Flexible cystoscopy is mandatory for all patients ≥ 40 years with microscopic hematuria and for any patient with gross hematuria; it offers superior patient comfort with diagnostic accuracy comparable to rigid cystoscopy【142】.
• Bladder cancer accounts for 30‑40 % of gross hematuria cases and 2.6‑4 % of microscopic hematuria cases, underscoring the need for direct visualization【142】.

Follow‑Up After a Negative Initial Work‑up

• In patients with persistent hematuria but a negative complete urologic evaluation, repeat urinalysis should be performed at 6, 12, 24, and 36 months, with concurrent blood‑pressure monitoring【142】.
• After two consecutive annual urinalyses that are negative, further testing can be discontinued【142】.
• High‑risk patients with ongoing microscopic hematuria should consider repeat cystoscopy and imaging within 3‑5 years【142】.

Immediate Re‑Evaluation Triggers

• Development of gross hematuria, a marked increase in microscopic RBC count, new irritative urinary symptoms, or emergence of hypertension/proteinuria (suggesting glomerular involvement) all mandate prompt repeat urologic assessment【142】.

Special Considerations for Elderly Patients

• Males ≥ 60 years are automatically classified as high‑risk and require both cystoscopy and CT urography regardless of other factors【142】.
• Females ≥ 60 years with any additional risk factor (e.g., smoking, gross hematuria, > 25 RBC/HPF) also require full urologic evaluation【142】.

Evaluation of Hematuria: When a Positive Dipstick Requires Microscopic Confirmation

Reliability of Dipstick Testing

• The American Urological Association states that a dipstick reading suggesting hematuria should not lead to imaging or invasive investigation unless microscopic analysis confirms ≥ 3 red blood cells per high‑power field (RBC/HPF). 143

Mandatory Microscopic Confirmation

• Order a microscopic urinalysis on a properly collected clean‑catch midstream urine specimen as the next step after a positive dipstick (≥ 1+ blood). 143
• If microscopy shows < 3 RBC/HPF, the result is considered normal; no further urologic work‑up is required. 143
• If microscopy shows ≥ 3 RBC/HPF, true microscopic hematuria is confirmed and the patient should undergo risk‑stratification for further evaluation. 143

Risk Stratification – High‑Risk Features Requiring Full Urologic Evaluation

• Age ≥ 35 years (or ≥ 40 years in some guidelines; the American Urological Association recommends using the lower threshold of 35 years for males) is a high‑risk criterion. 143

(Other high‑risk factors such as heavy smoking, prior gross hematuria, occupational exposures, irritative voiding symptoms, and hematuria > 25 RBC/HPF are mentioned in the article but lack a cited source and are therefore omitted from this evidence‑based summary.)

Bottom‑Line Diagnostic Algorithm (American Urological Association)

Strength of evidence: The recommendations are based on consensus statements from the American Urological Association (2012) and are classified as guideline‑level guidance rather than graded evidence from randomized trials.

Evaluation of Microscopic Hematuria When Renal Ultrasound Is Normal

1. Diagnostic Confirmation of True Hematuria

• Confirm true microscopic hematuria by obtaining a fresh microscopic urinalysis on a clean‑catch midstream specimen showing ≥ 3 red blood cells per high‑power field (RBC/HPF); dipstick testing alone has only 65–99 % specificity and may yield false‑positive results. 144
• Examine urinary sediment for dysmorphic RBCs (> 80 % of cells) and red‑cell casts; the former suggests a glomerular source, while casts are pathognomonic for glomerular disease. 144

2. Limitations of Ultrasound in Hematuria Work‑up

• Renal ultrasound cannot reliably evaluate the ureters, bladder mucosa, or detect small urothelial carcinomas, which are essential components of a complete hematuria assessment. 144
• The absence of hydronephrosis on ultrasound does not exclude ureteral stones; many stones—especially small ones—do not cause hydronephrosis, and dehydration can mask obstruction. [145][146]
• Absent ureteral jets on ultrasound are non‑specific and may result from an under‑distended bladder, technical limitations, or intermittent obstruction; they should not be used to rule out pathology. 145

3. Upper‑Tract Imaging Recommendations

• Multiphasic CT urography (unenhanced, nephrographic, excretory phases) is the preferred imaging modality, providing 96 % sensitivity and 99 % specificity for renal cell carcinoma, transitional cell carcinoma, and urolithiasis. 144
• CT urography outperforms ultrasound by evaluating kidneys, collecting systems, ureters, and bladder in a single study and detecting stones as small as 1–2 mm. 144
• When CT is contraindicated (severe renal insufficiency or contrast allergy), MR urography or renal ultrasound with retrograde pyelography are acceptable, though less optimal, alternatives. 144

4. Lower‑Tract Evaluation (Cystoscopy)

• Flexible cystoscopy is mandatory for any patient with microscopic hematuria who is ≥ 40 years old or possesses any high‑risk feature, allowing direct visualization of the bladder mucosa, urethra, and ureteral orifices. 144
• Bladder cancer accounts for 30–40 % of gross hematuria cases and 2.6–4 % of microscopic hematuria cases; imaging alone cannot exclude it, making cystoscopic visualization essential. 144
• Flexible cystoscopy is preferred over rigid cystoscopy because it causes less pain while offering equivalent or superior diagnostic accuracy. 144

5. Risk Stratification for Full Work‑up

All the above risk factors are supported by the same evidence source. 144

6. Laboratory Evaluation Prior to Imaging

• Measure serum creatinine and BUN to assess renal function before administering contrast for CT urography. 144
• Obtain a urine culture if infection is suspected, preferably before initiating antibiotics. 144
• Perform voided urine cytology in high‑risk patients (age > 60 years, smoking > 30 pack‑years, relevant occupational exposures) to detect high‑grade urothelial carcinoma or carcinoma in situ. 144

7. Critical Pitfalls to Avoid

• Do not dismiss hematuria based solely on a normal ultrasound; it is a screening tool, not definitive. 144
• Do not attribute hematuria to anticoagulant or antiplatelet therapy without completing the full work‑up; these agents may unmask underlying disease but do not cause hematuria. 144
• Do not delay urologic evaluation while pursuing other diagnoses; flank pain plus hematuria warrants urgent assessment to rule out obstructing stones or malignancy. 144
• Absent ureteral jets on ultrasound should not be over‑interpreted; the finding has limited clinical utility and does not exclude pathology. 145

8. Follow‑up Protocol When Initial Work‑up Is Negative

• Repeat urinalysis at 6, 12, 24, and 36 months, with blood pressure measurement at each visit. 144
• Immediate re‑evaluation is required if gross hematuria appears, microscopic hematuria markedly increases, new urologic symptoms develop, or hypertension/proteinuria/glomerular bleeding emerges. 144
• After two consecutive negative annual urinalyses, further testing is generally unnecessary. 144

9. Practical Management Algorithm (Condensed)

Guideline for Evaluation of a Positive Urine Dipstick for Hemoglobin

Initial Assessment and Interpretation

• A positive urine dipstick for hemoglobin indicates the presence of heme‑containing substances (intact red blood cells, free hemoglobin, or myoglobin) and requires microscopic urinalysis showing ≥3 RBCs per high‑power field (HPF) to confirm true hematuria before any further work‑up. 147
• The American Urological Association explicitly states that dipstick results alone must not trigger imaging, cystoscopy, or urologic referral; microscopic confirmation is mandatory. 147

Confirmation Protocol

• Order microscopic urinalysis on a clean‑catch midstream specimen to verify the dipstick finding. 147
• If microscopy shows <3 RBCs/HPF, document the result as normal and discontinue the hematuria work‑up. 147
• If microscopy shows ≥3 RBCs/HPF, true microscopic hematuria is confirmed and the patient should undergo risk stratification for urologic evaluation. 147
• For patients without high‑risk features, hematuria must be confirmed on two of three properly collected specimens before proceeding to imaging or endoscopy. 147
• High‑risk patients (age ≥35–40 years, smoking >30 pack‑years, prior gross hematuria, occupational chemical exposure, irritative voiding symptoms) require full evaluation after a single positive specimen. 147

Differentiating Hematuria, Hemoglobinuria, and Myoglobinuria

All distinctions are based on the same guideline source. 147

Risk Stratification for Confirmed Microscopic Hematuria

High‑Risk Features (mandate cystoscopy + CT urography)

• Age ≥35–40 years (men) or ≥50–60 years (women)
• Smoking history >30 pack‑years
• Any prior episode of gross hematuria, even if self‑limited
• Occupational exposure to benzenes, aromatic amines, or industrial chemicals/dyes
• Irritative voiding symptoms (urgency, frequency, dysuria) without documented infection
• Degree of hematuria >25 RBCs/HPF

Intermediate‑Risk Features (shared decision‑making)

• Age 40–59 years (men) or 50–59 years (women) with lower‑risk characteristics
• Smoking history 10–30 pack‑years
• Hematuria 11–25 RBCs/HPF

Low‑Risk Features (may defer extensive imaging)

• Age <40 years (men) or <50 years (women)
• Never smoker or <10 pack‑years
• Hematuria 3–10 RBCs/HPF

Risk categories are defined by the American Urological Association. 147

Imaging and Endoscopic Evaluation

• Multiphasic CT urography is the preferred upper‑tract imaging modality, offering 96 % sensitivity and 99 % specificity for renal cell carcinoma, transitional cell carcinoma, and urolithiasis. 147
• CT urography evaluates kidneys, collecting systems, ureters, and bladder in a single study, eliminating the need for additional imaging. 147
• When CT is contraindicated (severe renal insufficiency or contrast allergy), MR urography or renal ultrasound with retrograde pyelography are acceptable alternatives. 147
• Flexible cystoscopy is mandatory for all patients ≥40 years with microscopic hematuria or any patient with gross hematuria to visualize the bladder, urethra, and ureteral orifices. 147
• Bladder cancer accounts for 30–40 % of gross hematuria cases and 2.6–4 % of microscopic hematuria cases; imaging alone cannot exclude malignancy. 147
• Flexible cystoscopy provides diagnostic accuracy equivalent to or greater than rigid cystoscopy with less patient discomfort. 147

Laboratory Evaluation

• Serum creatinine and estimated glomerular filtration rate (eGFR) should be obtained to assess renal function. 147
• A spot urine protein‑to‑creatinine ratio >0.5 g/g suggests glomerular disease. 147
• Urine culture must be performed before initiating antibiotics when infection is suspected. 147
• Voided urine cytology is recommended in high‑risk patients (age > 60 years, smoking > 30 pack‑years, occupational exposures) to detect high‑grade urothelial carcinoma. 147

Glomerular vs. Non‑Glomerular Hematuria

Glomerular Indicators (prompt nephrology referral)

• > 80 % dysmorphic RBCs on urinary sediment
• Presence of RBC casts (pathognomonic)
• Protein‑to‑creatinine ratio >0.5 g/g
• Elevated serum creatinine or declining eGFR
• Tea‑colored or cola‑colored urine
• Co‑existing hypertension

Non‑Glomerular Indicators (focus on urologic evaluation)

• Predominantly normal‑shaped RBCs with minimal proteinuria
• Absence of RBC casts or dysmorphic RBCs
• Normal renal function

Even when glomerular features are present, urologic evaluation remains necessary because malignancy can coexist with renal disease. 147

Management Pitfalls to Avoid

• Never ignore gross hematuria; it carries a 30–40 % risk of malignancy and requires urgent urologic referral. 147
• Do not attribute hematuria to anticoagulant or antiplatelet therapy without completing the full diagnostic work‑up; these agents may unmask underlying pathology but do not cause hematuria. 147
• Do not rely solely on dipstick testing; microscopic confirmation of ≥3 RBCs/HPF is required before initiating any further evaluation. 147
• Do not delay evaluation in patients ≥35–40 years with confirmed hematuria, even if a benign cause is suspected. 147
• Phenazopyridine (Azo dyes) interferes with urinalysis; discontinue 48–72 hours before testing to avoid false results. 147

Follow‑Up Protocol

• Repeat urinalysis (including microscopy) at 6, 12, 24, and 36 months, with blood pressure monitoring at each visit. 147
• After two consecutive negative annual urinalyses, further testing is unnecessary. 147
• Immediate re‑evaluation is required if any of the following occur: new gross hematuria, marked increase in microscopic hematuria, emergence of urologic symptoms, or development of hypertension, proteinuria, or glomerular bleeding. 147
• High‑risk patients with persistent hematuria should consider repeat cystoscopy and imaging within 3–5 years. 147